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1. Introduction 
 
1.1 Malaria 
 
Malaria is a parasitic disease caused by Plasmodium protozoa and, with tuberculosis 
and HIV, is the third cause of death in the world. Five Plasmodium species ar known 
to be infectious to humans: P. falciparum, P. vivax, P. ovale, P. malariae and P. knowlesi. 
These parasites are responsible for different manifestation of this pathology, with P. 
falciparum being the most deadly. In 2011, it has been estimated that 3.3 billion people 
were at risk of contracting malaria, especially in the sub-Saharan regions. According 
to the World Health Organization’s data, 91% of the deaths due to malaria involved 
the regions of Africa (particularly sub-Saharan Africa), where the most affected 
people are children under 5 years and pregnant women (Figure 1.1).1  
While Africa is at great risk, western Asia, the Middle East and Latin America are 
also regions with a great risk of malaria transmission, and even first world country, 
where malaria has been eradicated, are at risk of reintroduction due to migratory 
fluxes.  
 
Figure 1.1 
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Geographical factors like temperature, humidity and rain are responsible for the 
distribution of the disease, limiting the ideal mosquito breeding ground in the 
tropical and subtropical regions. This localization had led many to consider malaria a 
“poverty disease”, because these area are often associated with poor economical, 
social and health conditions typical of third world countries. What is often 
overlooked is that the disease is also one of the causes of impoverishment in these 
countries: in high-risk of transmission area, malaria causes an average loss of 
economic annual growth of 1.3%. This fact can be observed comparing the GDP of 
countries where malaria is endemic and those where it has been eradicated. The 
infection has a direct impact on human resources because hinders social 
development and decreases school attendance,2 and direct costs of malaria include 
public and private spending for prevention and treatment of the disease. In some 
countries, malaria is the cause of 40% of public health expenditure, 39-50% of 
hospital admissions and 60% of day care consults. 
Every year between 10,000 and 12,000 cases of imported malaria are reported.2 In the 
European Union, the majority of imported malaria cases can be found in France, the 
United Kingdom, Germany and Italy. 
For over 50 years alkaloids of Cinchona and their derivatives have been used to 
control malaria. Chloroquine, a synthetic derivative of natural alkaloid quinine, has 
been one of the most effective anti-malarial drugs ever produced, but P. falciparum 
strain resistant to this class of drugs, first observed in South East Asia and South 
America, are now common also in Africa and Asia. This has led to a global 
resurgence of malaria, and the global effort to identify another therapeutic agent 
effective against malaria. This research led to the identification of artemisinin, a 
terpene extracted from Artemisia Annua. 
Artemisinin, a very effective antimalarial and expensive compound, quickly became 
a first line drug. Unfortunately, in some regions, resistance to this class of antimalaric 
has already been observed.3 
Therefore, there is a huge need to develop new antimalarial agents that, compared to 
traditional drugs, will be active against these resistant strains with improved 
pharmacokinetic properties, fewer side effects and lower costs. 
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1.2 Parasite life cycle 
 
Malaria is transmitted from person to person almost exclusively by a female 
mosquito of the genus Anopheles, though cases of accidental transmission due to 
blood transfusions or use of contaminated syringes have been reported. 
 
 
Figure 1.2  
 
Infected mosquitoes are able to transmit malaria with every bite during its life cycle, 
inoculating the infectious forms of the parasite, called sporozoites. Sporozoites 
remain in circulation for less than half an hour, after which they move into the 
parenchymal cells of the liver, starting the hepatic phase. During this phase, the 
sporozoites undergo a first cycle of asexual multiplication with the production of 
plurinuclear schizonts which then divide into intracellular mononuclear merozoites. 
Infected hepatocytes then break and release merozoites into the blood stream, where 
they adhere to the red blood cell (RBC) membrane and infect the erythrocytes, 
starting the second asexual phase called "red-cell cycle". Merozoites turn in 
trophozoites which are recognizable under the microscope due to typical ring shape. 
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Trophozoites initially grow feeding on hemoglobin, maturing to the stage of schizont 
with the ability to generate new merozoites. After a series of nuclear divisions, 
schizonts break free from the infected RBC and release numerous merozoites (from 6 
to 36 per schizont), able to start a new invasion (Figure 1.2). 
Malaria symptoms are characterized by fever (due to the breakdown of red blood 
cells and the subsequent invasion of new erythrocytes), shivers, splenomegaly and 
anemia. 
Depending on the Plasmodium species infecting the host, the infection cycle repeats at 
regular intervals: in cases of P. falciparum (malignant tertian malaria), P. ovale and P. 
vivax (benign tertian malaria) fever appears every 48 hours, while in the case of P. 
malariae (quartan malaria) every 72 hours. RBC destruction causes anemia, while in 
several vital organs microvasculature clots consisting of erythrocytes fragment leads to a 
blockage of blood vessels, causing decreased oxygenation of organs such as liver, kidneys or 
brain (cerebral malaria), which my lead to death.
4
 
P. vivax and P. oval hepatic parasites may persist in the liver as hypnozoites to 
generate, even after months or years, new infections of red blood cells known as 
"malarial relapse". 
In order to complete the replication cycle, some trophozoites may transform into 
male and female gametocytes. After a mosquito bites an infected person, ingesting 
the sexual forms, they maturate in its stomach (sporogonic cycle), producing 
numerous oocyst. The oocyst become sporozoites and accumulate in the salivary 
glands of the vector. Subsequent bites are capable of transmitting malaria to a new 
subject. 
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1.3 Pathogenesis 
 
The parasites presence inside the erythrocytes causes significant changes in the RBC 
membrane in order to replicate and avoid detection. Protuberances called knobs, 
consisting in specific proteins of the parasite (HRP-"histidin rich protein"), appear on 
the RBC membrane and adhesion of parasitized erythrocytes on vascular 
endothelium lead to the formation of rosettes (aggregates composed by a parasitized 
red blood cell surrounded by RBC not parasitized and 4-hydroxynonenal [4-HNE]).5 
The phenomenon of adhesion and occlusion of capillaries together with the high 
production of inflammatory factors, such as NO and TNF, is responsible of tissue 
damage, hypoxia and metabolic acidosis that characterize cerebral malaria and cause 
its symptoms.6 
Anemia, that can be observed in cases of severe malaria (SMA), is a complication 
caused by P.falciparum due to the loss of parasitized or not parasitized erythrocytes, 
coupled with a reduced erythropoiesis.7 That can be characterized by a reduction of 
the number of circulating reticulocytes, a normal or increased production of 
erythropoietin (EPO) and the altered morphology of erythroid precursors.8,9 
 
1.4 Red Blood Cells Membrane Remodeling 
 
 
Figure 1.410 
 
The Plasmodium parasite is one of the few pathogens able to invade ad overtake 
mature erythrocytes. In order to infect these cells, the parasite create a localized 
disorganization of the RBC membrane architecture, introducing various features, like 
adhesive and permeability properties,  necessary for its survival (Figure 1.4).11-13 
 
                                                                                                                                                                                                   Introduction 
 
8 
 
A group of parasite proteins, a complex called exportome, is responsible for the 
modifications imposed on the erythrocytes membrane, and a complex mechanism 
regulates the trafficking of these proteins over the plasma membrane and the 
parasitophorous vacuole (PV) in which the parasite resides and selectively direct 
them at specific sites of the host cell.14-17 
The exported proteins modify the architecture of the erythrocyte membrane, affect its 
elasticity and facilitate the transport of adhesins on the surface of red blood cell. To 
regulate proteins transport within the red blood cell, the parasite develops new 
membranous structures in the cytoplasm of the host cell, known as the 
tubulovescicular network and Mauer’s clefts.18-20 
The human erythrocyte is a highly specialized cell, tasked of carrying oxygen to the 
tissues. While the terminal stages of maturation lead to a loss of the nucleus and the 
ability to synthesize protein, its membrane allows him to make a journey of over 500 
km inside the blood vessels, suffering extreme deformations without incurring in any 
lethal fragmentation.21 This remarkable elasticity and resistance is conferred by the 
presence of a hexagonal membrane skeleton consisting in spectrin heterodimers, 
which associate to form tetramers.22 The deformability of the red cell membrane is 
partially due to the structural flexibility of the linker that connect the helical 
tetramers of spectrin and in part to the ability of tetramers to associate and dissociate 
to accommodate the distortions imposed by the circulation in the blood vessels,23-26 
and genetic defects of the proteins that compose the membrane skeleton results in 
hemolytic anemia.27-29 
The lack of a phagocytosis mechanism is one of the first problems that the parasite 
has to face to initiate the infection. In the initial stages the surface proteins of the 
merozoite, EBA175 and EBA140, bind to sialoglycoproteins and glicoporine A and C 
present on the membrane of the red blood cell, or otherwise use proteins capable of 
promoting invasion strategies independent from the presence of sialic acid.10 
After a bond between the two cells is established, the activation of an actine-miosine 
motor30 allows the penetration into the host cell. Simultaneously, lipids and proteins, 
including proteases, are secreted on the red blood cells membrane by some 
organelles known as rhoptri, micronemes and mononemes.31 The proteolytic activity 
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of these enzymes destroys the normal architecture of the cell membrane and its 
connections with the skeleton that supports it, releasing the membrane proteins.32-34 
In this phase of the invasion, the merozoite induces invagination of the membrane 
free of surface proteins,35 initiating the PV formation and completing the cell 
invasion.36 
During the final stages of the invasion, proteins secreted from rhoptri and dense 
granules are secreted into the PV and are transported, together with other proteins 
characteristic of the early stages, in the cytoplasm of the host cell, in order to initiate 
the cascades of events required for the remodeling of cell.37,38 The erythrocytes 
containing mature forms of new merozoites are sequestrated in various organs and 
removed from the bloodstream. The changes made by the plasmodium to the 
membrane give the RBC the ability to adhere to the endothelium via the formation of 
knobs (Figure 1.5), mainly consisting of knob-associated His-rich protein (KAHRP). 
These knobs act as platforms that expose a membrane protein responsible for 
adhering to endothelial cells and other vascular elements, called P. falciparum 
erythrocyte membrane protein 1 (PfEMP1).10 
Through this adhesion process the parasite is able to prevent phagocytosis by the 
spleen, and is associated with lethal complications such as cerebral and placental 
malaria.39,40 During the development of the parasite new structures extend from the 
PV membrane (PVM) in the cytoplasm of the host cell, forming the tubulovescicular 
network (TVN),40,41 and Maurer’s clefts appear along the plasmatic membrane of the 
red blood cells, probably originated by TVN.10 
Maurer’s clefts concentrate parasitic 
secretory proteins before transferring 
them to the erythrocyte membrane, 
although none of the proteins associated 
with these organelles showed significant 
homologies with enzymes that regulate 
the trafficking of proteins in higher 
eukaryotes. It has been hypothesized 
that the parasite developed a new 
Figure 1.5 
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system to direct proteins through the cytoplasm of the RBC.42-44 
Before the proteins can alter the cell membrane, they must cross both the PV and the 
PVM of the parasite to enter the cell cytosol. A hydrophobic domain at the N-
terminal serves as a signal sequence that facilitate the insertion into the endoplasmic 
reticulum and is required for transfer the proteins through the PV. In many cases, 
however, the presence of pentameric sequence is required to proceed through the 
PVM. 
The exportation of these proteins, therefore, depends on the presence in the sequence 
of the Plasmodium export element (PEXEL sequence), RxLxE/Q/D, an extremely 
conserved peptidic motifs identified in many Plasmodium species.45,46 Recognition of 
the Plasmodium export element gave the possibility to predict which proteins should be 
exported to allow the survival of Plasmodium within the erythrocyte, based on its 
presence within a sequence. 
Proteins to be exported are synthesized in the endoplasmic reticulum of Plasmodium 
and, after cleavage at the level of leucine in the PEXEL sequence and acetylation of 
the N-terminal, are transported into the host cell by an ATP-dependent translocone, 
known as complex PTEX.47 Mutations of R or L residues in the sequence lead to an 
attenuation of the cleavage process and proteins exportation, preventing the proper 
maturation of the plasmodium, revealing the great importance that the PEXEL 
sequence has in the parasite development processes.48,49 
 
1.5 Antimalarial therapies 
 
The first treatment used against malaria was the bark of Cinchona, discovered in Perù 
in 1600 and imported in Europe by the Jesuits. In 1800, chemists Pelletier and 
Caventou isolated the active ingredient from the Cinchona bark, an alkaloid called 
quinine. To answer the increasing demands of this drug, the Dutch planted large 
crops of Cinchona ledgeriana in their colonies in Indonesia. Cinchona bark contains 
other anti-malarial drugs (quinidine, cinchonine, cinchonidine) but quinine was the 
most used of them. For centuries, despite its side effects, quinine remained the only 
anti-malarial drug used in therapy. During World War I, the blockade of ports and 
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submarine attacks hindered the supply of quinine, and gave new inputs to the 
research of synthetic antimalarial drugs, generating in new molecules such as 
pamachine, primaquine and mepacrine. The need to protect the american troops in 
the Pacific during World War II, encouraged the development of even more potent 
antimalarial drugs. These research project led to the discovery of chloroquine, 
amodiaquine, pyrimethamine and proguanil.  
As chloroquine resistance appeared in South America and South East Asia in 1960, 
associations of sulfonamide with pyrimethamine and quinine with tetracycline were 
used. During the Vietnam War, mefloquine was discovered at the U.S. Army 
Research Institute "Walter Reed", but unfortunately mefloquine resistance appeared 
Thailand soon after its first use.  
A new therapeutic agents was identified by a government sponsored project aimed 
to research traditional Chinese medicine to find new molecules to be used against 
malaria. Extract of Artemisia annua was traditional be used for the treatment of fevers 
for many years. In 1971 artemisinin, a drug with no resemblance to the previous 
antimalarials, was isolated from Artemisia annua extract, and subsequently 
semisynthetic derivates artemether, artesunate and arteether were synthesized. 
Continuous studies are currently ongoing in order to discover and synthesize 
antimalarial drugs more effective and safe. 
Figure 1.6 shows the chemical structures of the most common antimalarial agents. 
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Figure 1.6 
 
In recent years, the widespread and indiscriminate use antimalarials has prompted 
the development of parasites with high levels of resistance to all classes of drugs.  
Combining two or more antimalarial drugs, with additive or synergistic action, may 
be used as a way to overcome parasite resistance. The ultimate goal is the effective 
elimination of the parasite, that can be achieved with the right combination of drugs 
with different properties. 
The half-life is an important parameter to be considered: if the component with lower 
half-life can eliminate most of the parasites (such as artemisinin and its derivatives), 
the second compound, with a longer half-life (eg. mefloquine and lumefantrine) is 
able to eliminate the few remaining parasites, decreasing the risk of developing 
resistance.50  
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Studies demonstrated that the synergistic interaction between atovaquone and 
proguanil (Malarone), is active against P. falciparum chloroquine resistant strains. The 
association between cycloproguanil and dapson (Lapdap) is another combination 
used in clinical study. 
Artemisinin and its analogues are frequently used in combination therapy due to 
their excellent chemical-physical properties, such as rapid-action, short half-life, 
limited toxicity and activity towards multi-drug resistant strains. 
Artemeter and lumefantrine in combination (Coartem) is effective against P. 
falciparum multidrug resistance and present no serious side effects. Other interesting 
combinations are artesunate (similar to artemisinin), with mefloquine, sulfadoxine-
pyrimethamine or dapson-chloroproguanil.51;52 However in 2006, the first case of 
resistance to artemisinin has been reported at the border between Thailand and 
Cambodia.53 
In 2011, the European Medicines Agency has approved Eurartisim, association of 
Diidroartemisin-piperaquine, developed by Sigma-Tau in collaboration with 
Medicines for Malaria Venture. 
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1.6 Resistance 
 
Resistance of P. falciparum against quinolines and in particular chloroquine led to an 
increase in the number of deaths caused by malaria.54 The areas characterized by the 
presence of parasites resistant to chloroquine or mefloquine are showed in Figure 1.7. 
 
 
Figure 1.7 
 
Chloroquine resistance is associated with a reduction drugs accumulated inside the 
digestive vacuole.54 
Both genetic and biochemical studies have attempted to explain the mechanism 
involved in chloroquine resistace. 
These theories include: 
 
 Alteration of the Na+/H+ pump, causing an increase in cytoplasmic pH and a 
reduction  chloroquine uptake;55 
 Pfmdr amplification, a gene involved in the overexpression of the protein Pgh-
1; 
 Digestive vacuole membrane mutations: P. falciparum cloroquine resistance 
transporter (PfCRT). 
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Martin and colleagues, in recent studies, showed the correlation between the PfCRT 
mutations and the chloroquine resistance.56 This protein is localized in the digestive 
vacuole membrane and has ten transmembrane domains. 
When a mutation of this protein occurs, in particular at Lys76 (K76T), it causes a 
modification of the first transmembrane domain and significant increase of 
chloroquine resistance is observed. Reed et al. have shown that the mutation of the 
protein Pgh-1 contributes not only to the chloroquine resistance but also modulate 
the resistance to other compounds such as mefloquine, alonfantrine and quinine.57 
Interestingly compounds strictly analogous to chloroquine are active on chloroquine-
resistant strains, demonstrating that the resistance is not due to target changes, but it 
is compound-specific. 
Mitochondrial DNA (mtDNA), with 6 kb of length, is quite unusual in malaria 
parasites and is the shortest mtDNA known;58;59 it is highly conserved and encodes 
for only three proteins (subunits I and II of cytochrome oxidase c and cytochrome b). 
Resistance to various cytochrome bc1 complex inhibitors is characterized by 
mutations in a defined region coding for the cytochrome b sequence and mutation in 
these region may explain the different toxicity of different hydroxynaphtoquinonic 
antimalarial. 58;59 The region of the cytochrome b implicated in the mechanism of 
resistance is part of the catalytic domain, site Q0, in which ubiquinol is oxidized by 
the complex bc. Mutations observed in P. yoelii resistant covers a region of 15 amino 
acids surrounding the highly conserved sequence of the cytochrome PEWY B.58;60;61 
Mutations alter the hydrophobicity and the volume of part of the binding cavity: 
therefore even slight variations can affect the affinity of atovaquone towards 
cytochrome bc1.58 Resistance to atovaquone is rapidly observed in P. falciparum 
infections when it is used as a single agent, and experimental evidence have shown 
that parasites that become resistant to atovaquone are also resistant to the synergistic 
effects of proguanil, to which atovaquone is usually associated.58 
Combination therapy based on derivatives of artemisinin or ACT (artemisinin 
combination therapy) provides an important alternative to quinoline derivatives. 
In the last decade almost all countries with endemic malaria adopted this ACT for 
the treatment of P. falciparum malaria. Artemisinin has a very short half-life and is 
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rapidly eliminated from the body due to glucuronidation by CYP 2B6.3 For this 
reason, this molecule is usually associated with long half-life antimalarial drugs such 
as piperaquine or amodiaquine.3 In 2006 the first case of resistance to artemisinine 
was reported in Ta Sanhal, a small city near the border between Thailand and 
Cambodia. The cause of resistance to artemisinin in South-East Asia has been 
attributed to the widespread use of this drug as monotherapy.62 
The World Health Organization (WHO), even before the artemisinine resistance was 
reported, banned artemisinin monotherapy to delay the development of resistance 
and protect these important derivatives for antimalarial therapy.  
In Vietnam, artemisinin is used to control malaria since 1989, and although current 
national guidelines recommend the use ACT, artemisinin and artesunate 
monotherapy are still widely available through the private sector. Vietnam is also 
one of the few countries where artemisinin monotherapy leaded to a highly 
successful program for the malaria control, with reported cases of malaria falling 
sharply from 1,672,000 with 4,650 deaths in 1991, 91,635 clinical cases with 43 deaths 
in 2006.62 
Current data suggest that resistance to artemisinin is simply a natural consequence of 
the massive use of ACTs in South East Asia.53 
 
1.7 Natural products privileged scaffolds in drug discovery 
 
Parasite resistance to many of agents currently employed in therapy is one of the 
main issues that hinder malaria eradication. 
In the quest for new therapeutics, natural products (NPs) have been an invaluable 
source of drug leads over many years.63-66 Natural products have played a dominant 
role in the cancer therapeutic area where, over the last 30 years, 74.8% of approved 
drugs are either natural products, based on natural products, or mimics of natural 
products.67 Up to 2006, 24 unique chemotypes from natural products produced 49 
marketed drugs.68 Numerous scaffolds identified in natural products have led to 
approved drugs or drug candidates for a range of diseases. Examples include 
antibacterials (β-lactams, tetracyclins, erythromycins), antivirals (modified 
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nucleosides), anticholesterolemics (lovastatin), and anti-tumour agents (rapamycins, 
epothilones).69 
Two recent reviews highlight the past achievements of natural products in providing 
new drugs, while at the same time providing a realistic evaluation of commitment 
within the pharmaceutical industry in the area of discovering new natural product 
drugs.70,71 
Harvey highlights the seminal work of Snader on drug prototypes.65 This work on 
the prototypes, the initial lead molecule developed to a candidate drug and then a 
marketed therapeutic, indicated that more than 80% of drug substances were natural 
products or inspired by natural products. 
While Harvey articulates the perceived disadvantages of NPs as  difficulty in access 
and supply, complexities of natural product chemistry, inherent slowness of working 
with natural products, concerns about intellectual property rights and hopes 
associated with the use of collections of compounds prepared by combinatorial 
chemistry methods, the review demonstrates the need to develop new approaches to 
take advantage of NPs. Shoichet et al. have examined the systematic absences in 
chemical biology/screening libraries and found that 83% (12,977) of core ring 
scaffolds present in natural products were absent from commercial collections.72 
Their analysis suggests that collections that include molecules containing scaffolds 
present in natural products will provide better opportunities to find both screening 
hits and chemical biology probes.  
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2. Aim of the Research 
 
Malaria causes 300 to 500 million clinical cases and more than 2.7 million deaths 
annually, almost entirely localized in Africa tropical regions and mostly involving 
children under the age of 5.73 There are four species that can cause this disease in 
humans: Plasmodium falciparum (Pf), Plasmodium vivax (Pv), Plasmodium ovale (Po) and 
Plasmodium malariae (Pm). Pf is the most virulent and is responsible for the high infant 
mortality. One estimate puts 40% of the world population in areas at risk of 
contagion and the threat is increasing in recent years due to global climate changes, 
insurgence of parasite strains resistant to drugs traditionally used and an increase in 
international travels. 
Despite the existence of effective therapies, the living conditions in most of the areas 
affected by the disease limit their use. Also, given their widespread use, low-cost 
drugs currently available are those against which the parasite has developed 
resistance, so there is a dire need of new antimalarial able to overcome the 
disadvantages of the drugs still in use, such as resistance and high costs.  
Plasmepsin V (PMV), the enzyme responsible for cutting the sequence PEXEL, plays 
a critical role in the maturation of merozoites during the early blood stages,74,75 
regulating the translocation of parasite proteins on the membrane of the red blood 
cells. Due to this central role in the onset and propagation of the disease, the 
inhibition of its activity appears to be a promising therapeutic target. The belonging 
of this enzyme to the family of aspartic proteases allows the use a classic approach in 
the development of new inhibitors. 
 
2.1 Plasmepsins 
 
The aspartic proteases present in the Plasmodium are considered one of the most 
promising target for the development of new antimalarial.76 To date, four 
homologous aspartic proteases have been characterized in detail, called plasmepsins 
(PMs). These four plasmepsins (PMI, PMII , PMIV and HAP), are digestive vacuole 
enzymes that are actively involved in hemoglobin degradation77,78 and may also been 
 
                                                                                                                                                                                  Aim of the Research 
 
19 
 
involved in the degradation of spectrin II and plasmepsin IV.79,80 The inhibition of 
these enzymes effectively blocks the parasite growth, and for this reason, plasmepsin 
have been considered as a possible therapeutic target.78,81,82 Six additional genes 
coding for plasmepsin76 and the mRNA of three of these genes (PMV, IX and X) are 
present in early stages of Pf infection.78 Immunofluorescence analysis showed that 
these plasmepsin are not localized in the digestive vacuole and, therefore do not take 
part in hemoglobin degradation.78 Recently, plasmepsin V (PMV) role has been 
clarified.74,75 This enzyme, localized in the endoplasmic reticulum, cleaves the PEXEL 
sequence that signals the need to export a protein. Aligning the sequence of PMV 
with other aspartic proteases of eukaryotic organisms showed many regions of high 
homology, revealing conserved structural and catalytic residues.83 In Figure 2.1, 
aspartate residues of the catalytic site are highlighted in yellow. A cysteine-rich 
region (Figure 2.1, blue), whose function has yet to be elucidated, has been identified 
in many aspartic proteases of plant origin.84 The C-terminal portion of the sequence 
contains a sequence of 25 hydrophobic aminoacids, whose function is to anchor the 
enzyme to the endoplasmic reticulum (Figure 2.1, red), and 15 other hydrophobic 
aminoacids are present in the N-terminal region, which serve as a signal sequence for 
the secretory system (Figure 2.1, green).83 
 
        10         20         30         40         50         60  
MNNYFLRKEN FFILFCFVFV SIFFVSNVTI IKCNNVENKI DNVGKKIENV GKKIGDMENK  
 
        70         80         90        100        110        120  
NDNVENKNDN VGNKNDNVKN ASSDLYKYKL YGDIDEYAYY FLDIDIGKPS QRISLILDTG  
 
       130        140        150        160        170        180  
SSSLSFPCNG CKDCGIHMEK PYNLNYSKTS SILYCNKSNC PYGLKCVGNK CEYLQSYCEG  
 
       190        200        210        220        230        240  
SQIYGFYFSD IVTLPSYNNK NKISFEKLMG CHMHEESLFL HQQATGVLGF SLTKPNGVPT  
 
       250        260        270        280        290        300  
FVDLLFKHTP SLKPIYSICV SEHGGELIIG GYEPDYFLSN QKEKQKMDKS DNNSSNKGNV  
 
       310        320        330        340        350        360  
SIKLKNNDKN DDEENNSKDV IVSNNVEDIV WQAITRKYYY YIKIYGLDLY GTNIMDKKEL  
 
       370        380        390        400        410        420  
DMLVDSGSTF THIPENIYNQ INYYLDILCI HDMTNIYEIN KRLKLTNESL NKPLVYFEDF  
 
       430        440        450        460        470        480  
KTALKNIIQN ENLCIKIVDG VQCWKSLENL PNLYITLSNN YKMIWKPSSY LYKKESFWCK  
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       490        500        510        520        530        540  
GLEKQVNNKP ILGLTFFKNK QVIFDLQQNQ IAFIESKCPS NLTSSRPRTF NEYREKENIF  
 
       550        560        570        580        590  
LKVSYINLYC LWLLLALTIL LSLILYVRKM FYMDYFPLSD QNKSPIQEST  
 
Figure 2.183 
 
Experiments conducted by Klemba and Goldberg and have confirmed that the PMV 
is an integral membrane protein.83 Despite PMV is related to the other nine 
plasmepsin present in P. falciparum, there is only a 17% identity with the sequence of 
mature PMIIs, while the identity between PMII and PMIV, both vacuolar 
plasmepsin, reaches 70%.76,85 During the course of the 44 hours necessary to complete 
a replication cycle of P. falciparum, the PMV is observed in small amounts during the 
first 12 hours. Its concentration increases during trophozoite (between 24 and 31 
hours) and schizont (between 31 and 41 hours) maturation. This increase of protein 
levels during development is similar to that observed for the digestive vacuole 
plasmepsin.78 In many aspartic proteases a specific region blocks the catalytic site 
and maintains the enzyme in an inactive state during translocation until it reaches its 
final destination.86 Plasmepsin I, II , IV and HAP possess a proregion including a 
transmembran dominion that anchor the proenzyme to the membrane during 
translocation into the digestive vacuole. The analysis of PMV proregion (Figure 1.6, 
underlined) of different Plasmodium species has revealed a high variability of the 
sequence, indicating the lack of important requirements for the structural or 
functional features of this region and supports the hypothesis that PMV is 
transported into the endoplasmic reticulum in unfolded and, therefore, does not 
require a mechanism to inhibit its activity.83 This mechanism has been observed in 
other aspartic proteases, including BACE, in which the proregion contributes to the 
correct folding of the catalytic site,87 and may have a similar role in PMV. In vitro 
inhibition of this enzyme was obtained using high concentrations of HIV protease 
inhibitors or pepstatin A, while other classes of inhibitors were ineffective. BACE 
inhibitors have little effect on the activity of PMV, probably due to the large 
evolutionary distance present between these two enzymes.75  
Further studies have shown that PMV is a essential protease present in the 
endoplasmic reticulum and P. falciparum parasite modified with a deletion of the 
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transmembrane portion were unable to maturate.83 While this results are promising, 
the lack of an efficient inhibitor of this enzyme limit the studies that could be 
performed to assess the viability of PMV as a new antimalarial target. With this 
work, we aim to synthesize peptidomimetic inhibitors to assess the structural and 
chemical requirements of the enzyme catalytic site, and compare them to the features 
present in recognized natural sequences. Data obtained will be used to design a set of 
compounds with reduced peptidic nature, that may be used as a starting point for a 
new series of antimalarial compounds. The main goal is to understand the 
therapeutic potential of PMV inhibition.  
 
 
                                                                                                                                                                                                       Discussion 
  
22 
 
3. Discussion 
 
3.1 Aspartic proteases inhibition 
 
The aspartic proteases are a family of proteolytic enzymes, mainly active at acid pH. 
The mechanism of action of these enzymes consist of the establishment of an acid-
base system which involves the two aspartates of the active site and a water molecule 
positioned between the two. The two aspartic acid residues act as a proton acceptor 
and donor, respectively, catalyzing the hydrolysis of the protein substrate. The water 
molecule is partially activated by an aspartate and performs a nucleophilic addition 
on a specific carbonyl of the peptide sequence: the carbonyl oxygen, in turn, captures 
a proton from the second aspartic acid of the active site, generating the tetrahedral 
intermediate, which converts into a stable product, resulting in the cleavage of the 
peptide sequence (Scheme 3.1).88 
 
 
Scheme 3.1 
 
Being part of fundamental processes in the development of various pathologies, the 
aspartic proteases have been for a long time the subject of study for the development 
of inhibitors that could block their activity and thus reduce the onset or development 
of diseases. Among the most known and studied there are renin, an integral part of 
the renin-angiotensin-aldosterone system that regulate blood pressure; BACE, 
responsible for the amyloid precursor protein cleavage, and HIV viral aspartic 
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proteases. The inhibition of these proteases has become an important therapeutic 
approach for the treatment of erectile disfuction, Alzheimer and AIDS.89  
The primary method used to inhibit the aspartic proteases is the use of bioisoster of 
the peptide bond that mimic the tetrahedral intermediate generated during the 
hydrolysis of the amide bond. The design of inhibitors of aspartic proteases exploits 
the formation of the transition state by introducing within the molecule an isosteric 
group that mimics the conformation of the intermediate, but it is not subject to the 
proteolytic activity of the enzyme. Isosteric groups as hydroxyethylaminic, 
hydroxyethilsulphidic and hydroxyethylureidic have successfully been used in the 
development of renin, viral protease and BACE inhibitors.88  
Following the identification of the PMV as a promising therapeutic target in the 
treatment of malaria, prof. Romeo’s group synthesized peptidic inhibitors of the 
enzyme, mimicking the PEXEL sequence but introducing an hydroxyethylamine 
moiety in place of the labile peptide bond, capable of effectively mimic the substrate 
transition state (Scheme 3.2). 
 
 
Scheme 3.2 
 
The HEA group was introduced within a sequence PEXEL replacing the peptide 
bond between the leucine and alanine. The first compound designed wanted to 
imitate as much as possible the sequence of the PMV substrate, RxLxE/Q/D (Figure 
3.1). 
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Figure 3.1 
 
The amino acids present in the various positions have been modified to study the 
interactions required to effectively inhibit the enzyme. Leucine(HEA) was 
maintained constant and multiple substitutions in other positions in the sequences 
were introduced. Since the localization of plasmodium within the red blood cell 
implies that PMV inhibitors should be able to cross biological membranes, the 
amount of charged residues in the sequences were kept to a minimum to allow the 
penetration of lipophilic membrane. The position P3 was the most studied due to its 
extreme conservation in the natural PEXEL sequences. Arginine is a basic amino acid 
with a long side chain, with a positive charge delocalized on the guanidine group at 
physiological pH, and these studies demonstrate how most modifications in the P3 
position led to inactive compounds. The compounds synthesized are shown in Table 
3.1. 
The compounds generated by prof. Romeo’s group are the first reported PMV 
inhibitors, but they were unable to inhibit parasite growth probably due to their 
unfavorable pharmacokinetic properties.90  
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Compound N-terminal P3 P2 P1 P1’ P2’ P3’ C-terminal PMV IC50 
(nM) 
LG21 H Arg Leu  Leu-HEA Ala Glu Ala OH 4 
LG25 H Met Leu Leu-HEA Ala Glu Ala OH inactive 
LG26 H Gln Leu Leu-HEA Ala Glu Ala OH 4900 
LG20 H Arg Leu Leu-HEA Ala Glu Ala NH2 1.6 
LG22 H Arg Ile Leu-HEA Ala Glu Ala NH2 228 
LG23 H Lys Leu Leu-HEA Ala Glu Ala NH2 3300 
LG29 H His Leu Leu-HEA Ala Glu Ala NH2 174 
LG30 H Trp Leu Leu-HEA Ala Glu Ala NH2 3 
LG37 H Tyr Leu Leu-HEA Ala Glu Ala NH2 3000 
SV01 H Arg Leu Leu-HEA Ala Gln Ala NH2 1.04 
LG32 H Lys Leu Leu-HEA Ala Gln Ala NH2 14000 
LG48 H Trp Leu Leu-HEA Ala Gln Ala NH2 700 
LG33 Bz Lys Leu Leu-HEA Ala Gln Ala NH2 inactive 
LG34 Ac Arg Leu Leu-HEA Ala Gln Ala NH2 75.6 
LG38 H Arg Leu Leu-HEA Tyr Glu Ala NH2 0.8 
LG44 H Arg Leu Leu-HEA Tyr Gln Ala NH2 10 
LG45 H His Leu Leu-HEA Tyr Gln Ala NH2 5000 
LG35 Ac Lys Leu Leu-HEA Pro Gln Ala NH2 inactive 
LG40 H Lys Leu Leu-HEA Ala Glu X NH2 1140 
LG46 H X Trp Leu-HEA Tyr Gln Ala NH2 inactive 
 
Table 3.1 
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3.2 Compounds stereochemistry 
 
Compounds generated using SPPS procedures present an undefined stereocenter 
due to the unselective reduction used in the HEA synthesis. During purification of 
compounds 2, 3, 4, 6, 8 and 9 it was possible to isolate a main peak and a secondary 
peak with the expected mass, probably corresponding to the two diastereoisomers.  
Biological testing revealed that the secondary peak possess, in all the instances, an 
inhibitorial activity lower than the main one. This different activity was already been 
observed by different research group working with HEA inhibitors of BACE-1. In 
these cases, the (R)-HEA moiety always showed a better activity compared against 
the same compound containing  the (S)-HEA group.91 
Literature data, also, report that unselective reduction of a carbonyl moiety during 
solid-phase synthesis preferentially generate the (R)-HEA over the (S)-HEA with a 
syn-anti ratio of 80:20 similar to the one observed in the synthesis of these class of 
compounds.92,93 
Experiments to determine the absolute configuration of these compounds are 
currently ongoing. 
 
3.3 SAR studies on peptidomimetics 
 
The first step in this research project was to increase the amount of structure-activity 
relationships of this class of compounds. Previous work was mainly focused on 
sampling the enzyme tolerance to different aminoacidic residues in the P3 position of 
the sequence. This position is the most conserved, and as expected very few 
modifications led to sequences recognized by the enzyme. Building upon that 
knowledge, my work aimed to assess the other position on the sequence in order to 
reduce the peptidic nature of this inhibitors and trying to achieve an inhibition of 
plasmodium growth.  
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3.3.1 P3’ position 
 
In compounds 1-4 (Figure 3.2) the C-terminal alanine was removed. This aminoacid 
was originally added to balance the compounds length, and it is not part of any 
specific PEXEL sequences.  
P3’ modifications does not seem to affect the activity of compounds 1 and 2, 
presenting an arginine in P3, but a complete loss of activity has been observed in 
previously active sequences containing a Trp in P3 (Compound 3 and 4). As 
observed in previous sequences, introduction of Tyr in P1’ slightly decrease the IC50, 
but it’s still considered a favorable modification since allows an easier purification 
process. 
 
 
 
Compound 
Pf 
PMV 
IC50 
[nM] 
Pf 
3D7 
IC50 
[µM] 
1 0.25 >200 
2 1.1/19.9 >200 
3 inactive ND 
4 inactive ND 
 
Figure 3.2 
3.3.2 P2’ position 
Compounds 5-8 (Figure 3.3) were synthesized in order to test the requirements 
present in P2’. Looking at the PEXEL sequences found in nature, the residue present 
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in this position is less conserved than the one occupying P3 and P1, but usually 
sports an acidic sidechain. Glutamic acid, aspartic acid and glutamine are equally 
found in this position when analyzing natural PEXEL sequences. Trying to 
understand the role of the acid group presents on the aminoacid sidechain, 
compounds 5 and 6, presenting a Gln residue in position P2’, were synthesized. 
While active, these compounds showed a nine-fold and a twenty-fold reduction in 
activity when compared with compounds 1 and 2. This shows that, while not 
necessary, the strong interaction of a glutamate residue in the S2’ is important for the 
activity of this class of compounds. 
To further explore the requirements of this pocket, a Gly residue was introduced 
(compounds 7 and 8). In order to maintain an acidic moiety in that position, the 
peptidomimetics were synthesized using 2-chlorotritylic resin, in order to obtain a 
carboxyterminal sequences. These compounds showed a good IC50 against PMV, and 
performed slightly better than compounds 5 and 6, while still being less active than 
compounds 1-2. 
 
Compound 
Pf 
PMV 
IC50 
[nM] 
Pf 
3D7 
IC50 
[µM] 
5 9 >200 
6 20/138 >200 
7 10 >200 
8 2/78 >200 
 
Figure 3.3 
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The last modification introduced was the complete removal of the aminoacid from 
the P2’ position (Figure 3.4). For synthetic reasons, the sequence synthesized was the 
one containing a carboxyterminal Tyr, easier to purify. This compound maintains 
only the two highly conserved residue Arg (in P3) and Leu (in P1), but lacks the 
acidic residue in P2’. 
As expected, compound 9 is almost unable to inhibit PMV activity, with an IC50 in 
the micromolar range, opposed to the other member of this class of inhibitor, that are 
usually in the low nanomolar range. 
 
Compound 
Pf 
PMV 
IC50 
[nM] 
Pf 
3D7 
IC50 
[µM] 
9 2500/9200 >200 
 
Figure 3.4 
 
3.4 Antiplasmodial activity of compounds 1-9 
 
Compounds 1-9 were tested for antimalarial activity against P. falciparum cultures. 
Despites their high inhibitorial activities against PMV, these compounds were unable 
to block parasite proliferation, as it was observed in compounds of the same class 
previously synthesized. This could be attributed to the highly peptidic nature of 
these molecules, which can hinder the peptidomimetic ability to cross biological 
membranes. In order to reach its site of action localized in the endoplasmatic 
reticulum, the compounds need to cross three different biological membranes (RBC 
membrane, PV membrane and finally the parasite membrane), each with different 
physiological properties that may not allow the diffusion of a multiple-charged 
compound. Also, both the erythrocytes and the parasites contain various kinds of 
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proteolytic enzymes, which may be able to cleave the sequences before they reach 
PMV.  
These factors could help to explain the poor performances of these compounds when 
tested against Pf cultures. Since these problems are linked to the peptidic nature of 
these class of compounds, and further modifications usually led to a loss of PMV 
inhibition properties, a new strategy was devised in order to design a new class of 
compounds that could target the PMV pathway, but without all the inherent 
complications arising from working with peptides. A natural product privileged 
scaffold was selected and used as a starting point upon which a small compound 
library was built in order to find a better candidate for drug development. 
 
3.5 Azaspiroundecane scaffold  
 
It has been observed that 83% of the cyclic scaffolds found in nature are not 
represented in commercially available products. These scaffolds have a complex 
three-dimensional structure, which could be exploited for biological interactions. An 
analysis performed by the research group of prof. Quinn (Eskitis Institute, Brisbane, 
Australia) has shown that these scaffolds, which are often main structural features of 
the molecule, are found in many natural products extracted from different biological 
sources. These structures, therefore, offer a versatility that can be exploited to obtain 
a suitably substituted compound possessing the characteristics of the molecules from 
which they derive, and thus eliminating the problems resulting from the total 
synthesis of individual natural products. One of the structures identified by the 
group of prof. Quinn is the 1-azaspiro[5.5]undecane  scaffold (Figure 3.5). 
 
 
Figure 3.5 
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Such scaffold is contained by a diverse set of natural products. There are at least 5 
distinct natural product chemical classes that have this scaffold embedded (Figure 
3.6). The spiro-scaffold is the clear three-dimensional determinant for all these 
molecules. 201 known lycopodium alkaloids, of which 70 belong to the quinolizidine 
class, contains this scaffold. An example of this structural class is lycopodine (Figure 
3.6).  
Erythrinane alkaloids, such as erythralin (Figure 3.6), have been isolated from a 
variety of plants belonging to the genus Erithrina, widely used in traditional 
medicine to treat a number of health problems including anxiety, insomnia and 
inflammation. This family of compounds has been reported to have anticonvulsant, 
hypotensive, hypnotic, analgesic and cytotoxic effects.94-96 
Cylindricines were isolated from the Tasmanian ascidian Clavelina cylindrical,97 and 
the related marine natural product, fasicularin (Figure 3.6) has selective activity 
against a DNA repair-deficient yeast strain.98  
Eudistone A (Figure 3.6) was isolated from the Seychelles tunicate Edistoma sp.,99 
while karachine (Figure 3.6) is a protoberberine alkaloid from Beberis arisata, used in 
the Unani system of medicine for the treatment of jaundice and skin diseases. 
 
 
Figure 3.6 
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3.6 Scaffold library 
 
Prof. Quinn work shows that the 1-azaspiro[5,5]undecane scaffold controls the 3D 
geometry of the compounds in which it is embedded. The orientation provided by 
the 3D geometry of the core scaffold seems to facilitate the interaction with the 
biological space, showed by the high proportion of active compounds in their 
synthetic library. Embedded 3D scaffolds occurring in natural products offer the 
potential to retain the biological relevant chemical space of natural products into 
libraries designed on these scaffolds. Starting from these observation, we used the 
same library used by prof. Quinn group to assess the adaptability of this scaffold in 
our project. Compounds 10-29 have been synthesized using the synthetic strategy 
devised during my stay in prof. Quinn group at the Eskitis Insitute, and they were 
tested in a single dose assay against Pf 3D7 cultures to assess their ability to inhibit 
plasmodium growth.  
Due to the extreme difficulty to assess PMV inhibition, compounds 10-19 were tested 
for their antimalarial properties before further investigation, using a single dose 
assay at high concentration (50 µM) against chloroquine-sensitive and chloroquine-
resistant strains of Pf was used as a preliminary screening.  
In this way we were able to screen the compounds in order to select only the one 
possessing antimalarial activity for further studies on PMV inhibition. 
Table 3.2 shows the activity of compounds 10-19, while the activity of compounds 
20-29 is currently under assessment. 
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Compound 
Pf 3D7 (D10) 
Growth inhibition % 
@ 50 μM 
Pf 3D7 (W2) 
Growth inhibition % 
@ 50 μM 
 
Scaffold A 
 
Inactive Inactive 
 
89.03 88.91 
 
25.41 36.34 
 
27.76 37.20 
 
28.44 30.76 
 
88.62 91.30 
 
85.68 78.94 
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99.48 98.80 
 
99.93 97.39 
 
85.19 85.63 
 
80.93  81.18 
 
Table 3.2 
  
3.7 Activity of compounds 10-19 
 
All compounds, beside 11-13 containing a bromine atom, showed a good inhibitorial 
activity when tested at 50 µM, while the unsubstituted scaffold A was unable to stop 
parasite growth. This is important since allow to rule out an unspecific activity due 
to the presence of the azaspiroundecane scaffold. Since the test was conducted using 
high concentration, it was not possible to observe significant differences in 
compounds activity and identify structure-activity relationships, but the presence of 
inactive compounds (11-13) suggest that a specific target with defined structural 
requirements may be at the base of their activity.  
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These observations led us to design two more compounds, using the SAR obtained 
working on the peptidomimetics in order to synthesize tailored compounds with 
better chances to interact with PMV. 
 
3.8 Design and activity of compounds 30-32 
 
In order to select the appropriate substituent, we looked at the SAR of 
peptidomimetics. Postition P3 was the most critical and the only aminoacid accepted 
in this position, with limited exception consisting in other basic aminoacids like Trp 
of Lys. Therefore, in compounds 30-32, the NP scaffold has been functionalized with 
L-arginine or 6-carboxyindole, in order to mimic the two most effective side-chain 
substitutions found in the SAR study. 6-Carboxyindole was selected in order to move 
away from peptide-like structures. Another advantage of using the spiro-scaffold is 
that the two nitrogen atoms were maintained at a similar distance when compared 
with the peptidomimetic inhibitors (6 bonds, Figure 3.5), and the cleavable bond was 
substituted with a carbamate, another bioisoster of the peptide bond already used in 
other aspartic proteases inhibitors, as Darunavir (Figure 3.5).100 
 
 
Figure 3.5 
 
When tested on Plasmodium cultures, compound 30, containing an arginine residue, 
showed no activity up to 50 μM, while both compounds 31 and 32 showed an 
activity in the low micromolar range (Table 3.3). 
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The reason of this could be due to the multiple charges present on the arginine 
residue, that could hinder the ability of this molecule to cross biological membrane, 
as observed in the peptidomimetic compounds. 
Compounds 31 and 32, the two diastereoisomer of the same molecule, showed 
different activities related to the different stereochemistry. 
 
Compound 
Pf 3D7 (D10) 
IC50 (μM) 
Pf 3D7 (W2) 
IC50 (μM) 
30 >50 >50 
31 12.8 16.5 
32 >20 >20 
 
Table 3.3 
 
Compounds 31 and 32, possessing an acceptable IC50 will soon be tested against PMV 
to assess their ability to inhibit this enzyme.  
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4. Synthesis 
 
4.1 Solid-Phase Peptide Synthesis 
 
The solid-phase peptide synthesis (SPPS) was conceived in 1963 by Merrifield in an 
attempt to solve the problems encountered in peptide synthesis using traditional 
methodology. 
This technique relies on an insoluble polymer matrix, suitably functionalized, acting 
as a physical support for the sequential growth of the peptide. The resin allows for an 
easy removal of unreacted reagents by simple filtration, avoiding laborious 
purification procedures after each synthetic steps. Bypassing the purification steps 
allow for the optimization of parallel synthesis strategies, and also the automation of 
the process. 
This approach evolved in recent years, allowing not only the synthesis of peptides, 
but to introduce modification in the peptidic sequences, such as disulfide bridge or 
unnatural aminoacids. 
During solid-phase synthesis, solubilized reagents reach the free functional groups 
present on the surface and in the inner part of the polymer granules only by 
diffusion: therefore the reaction is conducted using a large excess of reagents. 
Repeated washings and filtrations are then employed to remove the unreacted 
fraction. 
The synthesis (Scheme 4.1) begins with the formation of a covalent bond between the 
carboxy- terminal amino acid and the resin linker, followed by its deprotection and 
the insertion of the next amino acid, a loop that continues until the desired sequence 
is completed. The side chains of amino acids inserted must be protected with groups 
stable in the conditions used in the synthesis, but easily removable in selected 
conditions. The whole process is thus reduced to a series of cycles of coupling- 
deprotection that continue until the desired sequence is obtained, which will be 
finally cleaved from the resin.  
The nature of the terminal group can be selected using different type of linker. 
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The most common protecting groups used primarily the terminal amino groups are 
the t-butylcarbamate (Boc-) and the 9-fluorenylmethyl carbamate (Fmoc) groups. 
These two protecting groups require completely different synthetic strategies, as they 
are labile under different conditions and require specific orthogonal protections.  
The peptide bond formation is made possible by the presence of coupling reagent, 
such as carbodiimides or benzotriazoles. The cleaving methods used to detach the 
peptide sequences from the resin will vary depending on the type of resin, but they 
are usually carried out using a mixture containing different scavengers that mimic 
the functional groups present on the side chains, reducing the risk of parasite 
reactions during the cleavage step. 
 
 
 
Scheme 4.1 
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4.1.1  SPPS features and requirements  
 
The solid phase synthesis has many advantages compared to traditional synthesis: 
• simple work-up; 
• removal of secondary products, cleaved protecting groups and the excess reagents 
at the end of each reaction by simple filtration; 
• Possibility to increase reactions yields by working with large excess of reagents; 
• Avoid problems involving decreased solubility of the peptide during synthesis; 
• Easily automated process. 
 
The support used in the synthesis must be insoluble and chemically inert, with 
granule-size sufficient to allow the fast removal of the solvent by filtration. The 
support must swell quickly, to facilitate the reagents diffusion into its pores, and this 
reaction may be facilitated introducing a spacer that separates the inert matrix and 
the reactive sites. The solvent used in the reaction must be of intermediate polarity, 
such as CH2Cl2 or DMF. 
In optimal conditions, the coupling reaction should always be completed, in order to 
avoid the formation of peptides bearing deletions in the sequence that can complicate 
the final purification step. It is possible to perform, at the end of the coupling, a 
capping of unreacted amino groups by acylation, thus obtaining truncated sequences 
that no longer take part in subsequent coupling reactions. However, there is no 
guarantee that this operation will improve the overall yield , and therefore is often 
avoided. 
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4.2 Organic Reactions 
 
4.2.1 Aza-Michael Addition 
 
The Michael reaction, discovered in 1887, is one of the most important reactions in 
organic chemistry, consisting in the conjugated addition of a nucleophile on an 
unsaturated carbonyl compound, defined Michael acceptor. It consists in the 
nucleophilic attack at the β carbon of an α,β-unsaturated carbonyl compound33. 
Kohler better define the reaction as a 1,4 addition of a doubly stabilized nucleophilic 
carbon to a α,β-unsaturated carbonyl compound. If the functional group which acts 
as the nucleophile is an amine or another nitrogen containing moiety, such as 
carbamates, the reaction is classified as an aza-Michael. The mechanism of the 
reaction is illustrated below (Scheme 4.2). 
 
 
 
Scheme 4.2 
 
For many years the method used for the conjugated-addition between the carbonyl 
and the amino group required acidic or basic conditions and a catalyst. The reaction 
carried out in such environment was not applicable to industrial level, due to the 
numerous secondary products that could be formed in acidic or basic conditions 
High yields are usually observed in this reaction when applied to strong 
nucleophiles; while weak one, such as carbamates, are less prone to react and need a 
much more reactive catalyst. For the aza-Michael reactions involving a carbamate, 
metal catalysts have been studied and bismuth salts have showed a remarkably 
ability to catalyze this kind of reaction. 
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4.2.2 Bismuth role as a catalyst 
 
The success of the Michael reactions in the presence of bismuth nitrate stimulated 
researcher to try to understand the reaction mechanism.101 In absence of bismuth 
nitrate reagents are not completely converted and low product yields are observed. 
Bismuth nitrate produces small amount of nitric acid, which leads to an acid 
environment required for this type of reactions, although substituting bismuth 
nitrate led to decreased yields. These results suggested that the role of this catalyst is 
not only related to the formation of acid, but may be due to it action also as a 
complexing agent. The low yields obtained when the same reaction is catalyzed by 
other nitrate salts, such as sodium nitrate, iron nitrate and zinc nitrate, confirm the 
important role played by bismuth nitrate. The failure of these salts in promoting the 
reaction could be indicative of their inability to release sufficient amount of acid or 
create specific reactive-catalyst coordination complex. In conclusion, bismuth nitrate 
seems to be the catalyst with the ideal characteristics for the success of an aza-
Michael reaction. 
 
4.2.3 Ring-closing metathesis 
 
The ring-closing metathesis (RCM) involves the formation of a ring by the 
intramolecular reaction of two double bonds. The metathesis reaction was discovered 
around 1960 and the search for efficient catalysts led to the synthesis of many 
reagents. The efforts made for the development of this reaction led Robert H. Grubbs, 
Yves Chauvin and Richard R. Schrock to share the Nobel Prize for chemistry in 2005. 
Scheme 4.3 illustrates the reaction mechanism. 
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Scheme 4.3 
 
The formation of the cycle is usually entropically favored and the equilibrium can be 
shifted towards the product removing the ethylene liberated in the reaction. The 
amount of solvent used in the RCM is important, since an excessive or reduced 
dilution could lead to the formation of secondary products. The catalysts used in 
RCM reactions are metal-carbene compounds, and one of the most used the first 
generation Grubbs catalyst, containing ruthenium. Grubbs I catalyst (Figure 4.1) is a 
derivative of Ru(IV) with 16 electrons and, being less reactive than other catalysts, 
need to be used in a slightly higher quantity, usually 0.5-1%. The increasingly 
widespread use of this compound it is due to its excellent compatibility with most of 
the functional groups, except Lewis bases, and its greater air stability compared to 
other catalyst.102 
 
 
Figure 4.1 
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4.3 Reactions schemes 
 
Compounds 1-9 described above present an HEA core, a peptide bond isoster. The 
introduction of this group in a solid-phase synthesis approach is different from the 
normal procedures usually applied in this kind of synthesis, which mainly consists in 
the formation of peptide bonds between the amino acid residues. The HEA group 
was generated after reduction of the carbonyl moiety of an aminomethylketone, 
obtained by alkylation on the N-terminal amine of the peptide anchored to the resin. 
The alkylation was performed exploiting a nucleophilic substitution, which allows 
the formation of the bond between the methyl ketone of Fmoc-3-amino-1-bromo-5-
methylhexan-2-one and the amine of the last amino acid introduced (Scheme 4.4). 
The bromomethylketone (intermediate 1) was obtained by reaction of Fmoc-leucine 
with CH2N2 and subsequent treatment with HBr 48%, as described in literature.91 
 
 
 
Scheme 4.4 
 
Using an alkylation reaction instead of an acylation  generate a secondary amine, a 
group able to further reacts in the later stages of the synthesis, due to the large excess 
of reagents used in SPPS. This problem was solved by the introduction of a Boc 
protecting group, labile under the cleavage conditions. The reduction step was then 
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conducted in a solution of THF/EtOH (1:1), adding a large excess of NaBH4 (Scheme 
4.5). Not being stereoselective, the reduction produced both the diastereoisomers. 
 
 
 
Scheme 4.5 
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4.3.1 Synthesis of peptidomimetics 1-4 
 
Compounds 1-4, synthesized using Rink amide resin, are characterized by a terminal 
dipeptide Ala-Glu or Tyr-Glu that reacts with Fmoc-3-amino-1-bromo-5-
methylhexan-2-one to generate intermediates 2 and 3, the HEA group precursor 
(Scheme 4.6). 
 
 
 
Scheme 4.6 
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HEA group was generated in situ following the procedure showed in Scheme 4.5. 
Scheme 4.7 illustrates the final steps necessary to obtain compounds 1-4. 
 
 
 
Scheme 4.7 
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4.3.2 Synthesis of peptidomimetics 5 and 6 
 
Compounds 5 and 6, synthesized using Rink amide resin, are characterized by a 
terminal dipeptide Ala-Gln or Tyr-Gln that reacts with Fmoc-3-amino-1-bromo-5-
methylhexan-2-one to generate intermediates 4 and 5, the HEA group precursor 
(Scheme 4.8). 
 
 
 
Scheme 4.8 
 
HEA group was generated in situ following the procedure showed in Scheme 4.5. 
Scheme 4.9 illustrates the final steps necessary to obtain compounds 5 and 6. 
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Scheme 4.9 
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4.3.3 Synthesis of peptidomimetics 7 and 8 
 
Compounds 7 and 8, synthesized using 2-Chlorotrytil resin, are characterized by a 
terminal dipeptide Ala-Gly or Tyr-Gly that reacts with Fmoc-3-amino-1-bromo-5-
methylhexan-2-one to generate intermediates 6 and 7, the HEA group precursor 
(Scheme 4.10). 
 
 
 
Scheme 4.10 
 
HEA group was generated in situ following the procedure showed in Scheme 4.5. 
Scheme 4.11 illustrates the final steps necessary to obtain compounds 7 and 8. 
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Scheme 4.11 
 
4.3.4 Synthesis of peptidomimetic 9 
 
Compound 9, synthesized using 2-Chlorotrytil resin, is characterized by a single 
aminoacid in position P1’ that reacts with Fmoc-3-amino-1-bromo-5-methylhexan-2-
one to generate intermediate 8, the HEA group precursor (Scheme 4.12). 
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Scheme 4.12 
 
HEA group was generated in situ following the procedure showed in Scheme 4.5. 
Scheme 4.13 illustrates the final steps necessary to obtain compound 9. 
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Scheme 4.13 
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4.3.5 Synthesis of intermediates 10 and 11 
 
Intermediate 10 and 11 were synthesized according to the synthetic pathway 
illustrated below (Scheme 4.14). 
 
 
Scheme 4.14 
 
The scheme involves a reaction between the 2-cyclohexenone and benzyilcarbamate 
giving intermediate 9, and subsequent one-pot double allylation with formation of 
intermediates 10 and 11.The intermediates 10 and 11 are obtained in a ratio of about 
75:35, calculated on purified compounds. Table 4.1 shows the reactions yields. 
 
Intermediate IUPAC name Yield 
9 benzyl (3-oxocyclohexyl)carbamate 90.4% 
10 
benzyl ((1S±1R,3R±3S)-3-allyl-3-
(allylamino)cyclohexyl)carbamate 
50.6% 
11 
benzyl ((1S±1R,3S±3R)-3-allyl-3-
(allylamino)cyclohexyl)carbamate 
27% 
 
Table 4.1 
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4.3.6 Synthesis of scaffolds A and B 
 
Scaffolds A and B were synthesized according to the synthetic pathway illustrated 
below (Scheme 4.15). 
 
 
Scheme 4.15 
 
The scheme consists of three steps: the protection of the amine with formation of 
intermediate 12 or 13 starting from intermediate 10 or 11, respectively; cyclization of 
those intermediates using first generation Grubbs reagent, generating the 
intermediates 14 and 15; and catalytic hydrogenation with formation respectively of 
scaffolds A and B. Table 4.2 shows the reactions yields. 
 
Intermediate IUPAC name Yield 
12 
allyl(1R±1S,3S±3R)-1-allyl-3-
(((benzyloxy)carbonyl)amino)cyclohexyl)methylcarbamate 
72.7% 
13 
(allyl((1S±1R,3S±3R)-1-allyl-3-
(((benzyloxy)carbonyl)amino)cyclohexyl)methylcarbamate 
67.8% 
14 
(6R±6S,8S±8R)-methyl 8-(((benzyloxy)carbonyl)amino)-1-
azaspiro[5.5]undec-3-ene-1-carboxylate 
91% 
15 
(6S±6R,8S±8R)-methyl 8-(((benzyloxy)carbonyl)amino)-1-
azaspiro[5.5]undec-3-ene-1-carboxylate 
84.9% 
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A 
((6R±6S,8R±8S)-methyl 8-amino-1-azaspiro[5.5]undecane-
1-carboxylate 
99.8% 
B 
((6R±6S,8S±8R)-methyl 8-amino-1-azaspiro[5.5]undecane-
1-carboxylate 
68.6% 
 
Table 4.2 
 
4.3.7 Synthesis of compounds 10-19 
 
Compounds 10-19 were synthesized through a reductive amination reaction starting 
from Scaffold A (Scheme 4.16). 
 
 
Scheme 4.16  
 
                                                                                                                                                                                                          Synthesis 
  
56 
 
 
 
Scheme 4.16 (continued) 
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Table 4.3 illustrates the reaction yields of each compound. 
 
Compound IUPAC name Yield 
10 
(6R±6S,8R±8S)-methyl 8-(((6,6-dimethyldicyclo[3.1.1]ept-2-en-3-
yl)methyl)amino)-1-azaspiro[5.5]undecane-1-carboxylate 
18.2% 
11 
(6R±6S,8R±8S)-methyl 8-((2-bromobenzyl)amino)-1-
azaspiro[5.5]undecane-1-carboxylate 
95.7% 
12 
(6R±6S,8R±8S)-methyl 8-((3-bromobenzyl)amino)-1-
azaspiro[5.5]undecane-1-carboxylate 
94.5% 
13 
(6R±6S,8R±8S)-methyl 8-((4-bromobenzyl)amino)-1-
azaspiro[5.5]undecan-1-carboxylate 
90.9% 
14 
(6R±6S,8R±8S)-methyl 8-(isopentylamino)-1-
azaspiro[5.5]undecan-1-carboxylate 
77.8% 
15 
(6R±6S,8R±8S)-methyl 8-(benzylamino)-1-
azaspiro[5.5]undecan-1-carboxylate 
51.8% 
16 
(6R±6S,8R±8S)-methyl 8-(adamantan-2-yl)amino)-1-
azaspiro[5.5]undecan-1-carboxylate 
63% 
17 
(6R±6S,8R±8S)- methyl 8-((4-phenoxybenzyl)amino)-1-
azaspiro[5.5]undecane-1-carboxylate 
74.1% 
18 
(6R±6S,8R±8S)-methyl 8-((2,4-dimethoxybenzyl)amino)-1-
azaspiro[5.5]undecane-1-carboxylate 
66.7% 
19 
(6R±6S,8R±8S)-methyl 8-((naphthalen-2-ylmethyl)amino)-1-
azaspiro[5.5]undecane-1-carboxylate 
49.6% 
 
Table 4.3 
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4.3.8 Synthesis of compounds 20-29 
 
Compounds 20-29 were synthesized through a reductive amination reaction starting 
from Scaffold B (Scheme 4.17). 
 
 
Scheme 4.17 
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Scheme 4.17 (continued) 
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Table 4.4 illustrates the reaction yields of each compound. 
 
Compound IUPAC name Yield 
20 
(6R±6S,8S±8R)-methyl 8-(((6,6-dimethyldicyclo[3.1.1]ept-2-en-3-
yl)methyl)amino)-1-azaspiro[5.5]undecane-1-carboxylate 
10% 
21 
(6R±6S,8S±8R)-methyl 8-((2-bromobenzyl)amino)-1-
azaspiro[5.5]undecane-1-carboxylate 
3.85% 
22 
(6R±6S,8S±8R)-methyl 8-((3-bromobenzyl)amino)-1-
azaspiro[5.5]undecane-1-carboxylate 
38.5% 
23 
(6R±6S,8S±8R)-methyl 8-((4-bromobenzyl)amino)-1-
azaspiro[5.5]undecan-1-carboxylate 
10.8% 
24 
(6R±6S,8S±8R)-methyl 8-(isopentylamino)-1-
azaspiro[5.5]undecan-1-carboxylate 
23.1% 
25 
(6R±6S,8S±8R)-methyl 8-(benzylamino)-1-
azaspiro[5.5]undecan-1-carboxylate 
4.6% 
26 
(6R±6S,8S±8R)-methyl 8-(adamantan-2-yl)amino)-1-
azaspiro[5.5]undecan-1-carboxylate 
11.5% 
27 
(6R±6S,8S±8R)-methyl 8-((4-phenoxybenzyl)amino)-1-
azaspiro[5.5]undecane-1-carboxylate 
18.6% 
28 
(6R±6S,8S±8R)-methyl 8-((2,4-dimethoxybenzyl)amino)-1-
azaspiro[5.5]undecane-1-carboxylate 
13.1% 
29 
(6R±6S,8S±8R)-methyl 8-((naphthalen-2-ylmethyl)amino)-1-
azaspiro[5.5]undecane-1-carboxylate 
5.4% 
 
Table 4.4 
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4.3.9 Synthesis of compounds 30-32 
 
Compounds 30-31 were synthesized through a coupling reaction starting from 
Scaffold A, while compound 32 originate from scaffold B (Scheme 4.18). 
Scheme 4.18 
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Table 4.5 illustrates the reaction yields of each compound. 
 
Compound IUPAC name Yield 
Intermediate 
16 
(6S±6R,8S±8R)-methyl 8-((S)-5-(2,3-
bis((benzyloxy)carbonyl)guanidino)-2-((tert-
butoxycarbonyl)amino)pentanamido)-1-
azaspiro[5.5]undecane-1-carboxylate 
60.7% 
30 
(6S±6R,8S±8R)-methyl 8-((S)-2-amino-5-
guanidinopentanamido)-1-azaspiro[5.5]undecane-1-
carboxylate 
88.2% 
31 
(6S±6R,8S±8R)-methyl 8-(1H-indole-6-carboxamido)-1-
azaspiro[5.5]undecane-1-carboxylate 
34.6% 
32 
(6S±6R,8R±8S)-methyl 8-(1H-indole-6-carboxamido)-1-
azaspiro[5.5]undecane-1-carboxylate 
19% 
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 5. Conclusions 
 
In developing countries, endemic malaria epidemics preclude the possibility of 
economic progress and impose a high cost in terms of lost human life.103 The rapid 
onset of the Plasmodium resistance to therapeutic agents is forcing the research to 
develop new molecules and identify alternative targets to devise  an effective method 
to eradicate the parasite from infested areas. Thanks to the discovery the Plasmodium 
export element function,14 the characterization of the aspartic protease plasmepsin V83 
and the interaction between these two elements, which allows the plasmodium 
development,74,75 a new therapeutic target may be now available. Inhibition of PMV 
could stop the modification taking place on the erythrocytes membrane, which is 
necessary to make the RBC capable of supporting the parasite replication process.10 
 
In this work, I evaluated the potential of PMV inhibition as a new target for malaria 
treatment. The advantages in targeting this enzyme are due to its role in plasmodium 
maturation and its presence in gametocytes, that could allow inhibitors to act at 
different stages of the parasite life cycle.  
In order to assess the viability of this target, peptidomimetics compounds were 
synthesized to study the catalytic pocket of the enzyme, and to compare these 
findings with the natural sequences recognized by PMV (Figure 6.1). 
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Figure 6.1 
 
As described previously, the arginine and the leucine in the sequence are conserved 
among all the sequences that share this exportation mechanism.  
While usually, it is possible to observe some degree of difference among recognized 
natural sequences and the inhibitor sequences, our findings highlight that only other 
basic aminoacids could substitute the arginine residue. All other substitutions led to 
molecules with an activity greatly reduced, or inactive compounds. Only in six-
aminoacids peptidomimetics (Compounds 1-4, and previously synthesized 
compounds) modification of P3 position generated active compounds. 
Since positions P2 and P1’ do not show any degree of conservation, they were not 
explored except for synthetic reasons, introducing a Tyr residue in position P1’ to 
simplify the purification process.  
Position P2’, while requiring an acidic sidechain, it is less strict about the identity of 
the residue: glutamate is the most observed aminoacid in natural PEXEL sequences, 
but aspartate and glutamine are also tolerated. The same behavior was found in the 
peptidomimetic inhibitors, where switching from Glu to Gln gave active compounds, 
albeit with a 100-fold loss of activity (Compounds 1 and 5, Compounds 2 and 6). The 
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need for an acidic sidechain was confirmed substituting the glutamate with a 
carboxyterminal glycine: the free carboxylic acid can still interact with the 
aminoacids in the S2’ subsite, and both compounds possess a low micromolar IC50. 
While less conserved, though, the interaction of this residue with the subsite is 
necessary for the inhibitorial activity of the compounds, as showed by the lack of 
activity of compound 9. 
Structure and activity of compounds 1-9 are reported in Table 5.1. 
 
Compound Structure 
Pf 
PMV 
IC50 
[nM] 
1 
 
0.25 
2 
 
1.1/19.9 
3 
 
Inactive 
4 
 
Inactive 
5 
 
9 
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6 
 
20/138 
7 
 
10 
8 
 
2/78 
9 
 
2500/9200 
 
Table 6.1 
 
Structure-activity relationships of this class of compounds, obtained in this thesis and 
during previous work, could be summarized as following: 
 
 
 
 R1: Residues different from arginine are not well tolerated and lead to inactive 
compounds; 
 R2: Leucine or Isoleucine are equally accepted in this position; 
 R3: Tyr slightly decreases the activity of the peptidomimetic sequences but 
simplify the purification process; 
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 R4: Gln may replace Glu without significant loss of activity, and a –COOH 
terminal Gly is able to mimic the Glu sidechain; 
 R5: Removing this aminoacid from the sequence does not significantly affect 
the activity of the peptidomimetics; 
 R6: Alifatic capping groups maintain or increase the activity, while aromatic 
groups kill PMV inhibition. 
 
Since position P3, P1 and P2’ need to be occupied for this class of compounds, it is 
evident that five aminoacids is the minimum length to generate an active compound. 
This is an issue, since it complicates the task of reducing the peptidic nature of the 
molecules, and the charged sidechains seriously hinder the compounds ability to 
cross biological membranes. Due to localization of PMV, the lack of antiplasmodial 
activity of compounds 1-9 could be easily explained as an inability to reach their 
target at an effective concentration. 
Since this problem is intrinsically correlated to their peptidic nature, we decided to 
look into natural products in order to find a suitable scaffold to be used as a starting 
point for a new class of compounds. The existence of three-dimensional skeletons 
overrepresented in many natural products gave us the idea to exploit one of those 
structures, the 1-azaspiro[5,5]undecane, as a core scaffold. 
A small library of compounds was synthesized, and tested against P.f. cultures to 
evaluate their role as a useful starting point. The molecules presenting the 
azaspiroundecane scaffold (Scaffold A) demonstrate a remarkable ability to inhibit 
plasmodium growth at 50 µM, with just three compounds unable to go above 40% 
inhibition (Table 5.2), while the free scaffold is ineffective. These compounds are 
equally active against both chloroquine-resistant and sensitive strains, an important 
feature in the identification of new antimalarial.  
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Compound Structure 
Pf 3D7 (D10) 
Growth 
inhibition % 
@ 50 μM 
Pf 3D7 (W2) 
Growth 
inhibition % 
@ 50 μM 
Scaffold A 
 
Inactive Inactive 
10 
 
89.03 88.91 
11 
 
25.41 36.34 
12 
 
27.76 37.20 
13 
 
28.44 30.76 
14 
 
88.62 91.30 
15 
 
85.68 78.94 
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16 
 
99.48 98.80 
17 
 
99.93 97.39 
18 
 
85.19 85.63 
19 
 
80.93  81.18 
 
Table 5.2 
 
The high activity of these compounds at this concentration make it difficult to 
extrapolate any kind of structure-activity relationship, but the presence of low active 
molecules (compounds 11-13) and the inactive scaffold seem to suggest the presence 
of a defined mechanism of action.  
These data were used to design new molecules with more specific substituents. The 
SAR study performed using the peptidomimetic sequences provided the essential 
requirements for PMV inhibitors, and we decided to introduce a suitable substituent 
able to interact with S3 pocket of the catalytic site. Arginine was an obvious choice, 
but still marred by the presence of multiple positive charges on the guanidine group. 
6-carboxyindole was selected trying to overcome this problem, introducing a basic 
moiety less flexible and with less charges compared to arginine. 
In the scaffold, the distance (in bond length) between the two nitrogens match the 
bond distance occupied by the aminoacids usually found in position P2-P1, putting 
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the methylcarbamate moiety close to the cleaving position of the natural substrate. 
Carbamates have already been used as bioisosters of the peptide bond, as in the HIV 
aspartic protease inhibitor Darunavir, thus providing an optimal substituent for the 
endocyclic amine of the scaffold. 
Compounds 30 and 31 were synthesized and preliminary screened against PMV 
culture in order to assess their IC50. Compound 30, presenting some of the liability of 
the peptidomimetic compounds, resulted inactive, while compound 31 showed a low 
micromolar IC50. Its diasteroisomer, compound 32, was less active (Table 5.3). 
 
Compound Structure 
Pf 3D7 (D10) 
IC50 (µM) 
Pf 3D7 (W2) 
IC50 (µM) 
30 
 
>50 >50 
31 
 
12.8 16.5 
32 
 
>20 >20 
 
Table 5.3 
 
At this stage, unfortunately, there is no direct correlation between the activity of 
these compounds and PMV inhibition; however, they are based on deductive design 
built on SAR data of previously synthesized PMV inhibitors.  
Our collaborators are currently undergoing the assessment of PMV inhibition, but 
this work is hindered by difficulties in purifying the functional enzyme.  
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5.1 Closing remarks 
 
PMV is an interesting enzyme that regulate the trafficking of plasmodium proteins 
during the RBC membrane remodeling stage. Due to its central role in one of the 
fundamental steps of parasite infection, being able to interfere with PMV activity 
may provide a new strategy to fight the insurgence of plasmodium strains resistant 
to conventional therapies.  
While at this stage I could not positively identify PMV as a drugable target, my work 
on this enzyme shed light to some of the structural requirements that potential 
inhibitors should possess in order to efficaciously interact with the catalytic site. 
Moreover, the merging of this information with the exploitation of a natural product 
scaffold led to the identification of a new series of compounds that, while possessing 
an IC50 of low therapeutically interest, do not seem to share the same mechanism of 
action of chloroquine, and could be optimized during further studies to achieve a 
better activity. 
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6. Experimental Section 
 
6.1 Abbreviations 
 
A: Alanine; E: Glutamic acid; H: Histidine; I: Isoleucine; K: Lysine;  L: Leucine; M: 
Methionine; N: Asparagine; P: Proline; Q: Glutamine;  R: Arginine; W: Tryptophan; Y: 
Tyrosine; TBTU: 2-(1H-benzotriazol-1-il)-1,1,3,3-tetramethyluronium tetrafluoroborate;  
HOBt: 1-Hydroxybenzotriazole hydrate; DMF: N,N-Dimethylformamide;  DCM: 
Dicloromethane; NMP: N-Methyl pyrrolidone; DIEA: Diisopropyl ethylamine; Pip: 
Piperidine; MeOH: Methanol; Ac2O: Acetic anhydride; Boc2O: Di-tert-butyldicarbonate; 
THF: Tetrahydrofuran; EtOH: Ethanol; TFA: Trifluoroacetic acid;  NMM: N-methyl 
morpholine; SPPS: Solid phase peptide synthesis. 
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6.2 Reagents and Instrumentations 
 
NMR spectra were recorded at 30°C on either a Varian 500 or 600 MHz Unity 
INOVA spectrometer, the latter spectrometer equipped with a triple resonance cold 
probe (Eskitis Institute, Griffith University) or a Varian 300 MHz Mercury 
spectrometer (Dipartimento di Scienze Farmaceutiche, Università degli Studi di 
Milano), and referenced using the residual non-deuterated solvent peak.  
LR-ESIMS were recorded on a Mariner time-of-flight spectrometer equipped with a 
Gilson 215 eight-probe injector. 
LC-MS were recorded on a ZQ Waters ESI quadrupole LC-MS system. 
Spectrophotometric measurements were performed on a UV-VIS Perkin-Elmer LAMDA 11. 
HR-ESIMS were recorded on a Bruker Daltronics Apex III 4.7e Fourier-transform 
mass spectrometer. 
Alltech Davisil 40−60 μm 60 Å C18 bonded silica was used for preadsorption work. A 
Waters 600 pump equipped with a Waters 996 PDA detector and a Waters 717 
autosampler were used for HPLC. 
A Thermo-Electron C18 Betasil 143Å column (5 μm, 21.2 × 150 mm) was used for 
semipreparative HPLC separations. All solvents used for chromatography and MS 
were HPLC grade (RCI Lab-Scan, Sigma-Aldrich), and the H2O was Millipore Milli-Q 
PF filtered. Natural products used to test activity were isolated in previous work at 
the Eskitis institute and are part of its collection. All reagents were commercially 
obtained (Sigma-Aldrich, Acros, Boron Molecular, IRIS Biotech GmbH, Carlo Erba 
Reagenti) at highest commercial quality and used without further purification. Air- 
and moisture-sensitive liquids and solutions were transferred with a syringe. All 
reactions were carried out under anhydrous conditions with within an argon 
atmosphere in dry solvents, unless otherwise noted. Yields refer to 
chromatographically and spectroscopically (1H NMR, LC, MS) homogeneous 
materials, unless otherwise stated. Reactions were monitored by thin-layer 
chromatography carried out on 0.25 mm Merck silica gel plates (60F-254) with UV 
light as the visualizing agent and permanganate stain solution as developing agent. 
Merck silica gel (60, particle size 0.040–0.063 mm) was used for flash 
chromatography. 
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Resins, Fmoc-aminoacids, solvents and reagents used for SPPS were obtained from IRIS 
Biotech GmbH (Schnelldorf, Germany), Carlo Erba Reagenti (Rodano, Italia) and Sigma-
Aldrich (Schnelldorf, Germany) and used without further purification. Peptides were 
manually synthesized using polypropylene syringes (10 ml) with polyethylene frits bought 
from Grace Discovery. 
 
6.3 SPPS General Procedures 
The peptide synthesis was performed on solid phase, using the Rink amide resin (150 
mmol; loading: 0.46 mmol/g) or the 2-chlorotrityl resin (150 mmol; loading 1.55 
mmol/g). 
 
6.3.1 Resin-specific Solid-Phase Procedures 
 
 Rink amide resin 
  
 
 
The rink amide resin presents a Fmoc-protected amine that need to be cleaved in 
order to activate the resin. 
a) Swelling 
The resin is suspended in a solution of NMP (1 ml per 150 µmol of resin) and DCM 
(7.5 ml) and left in a ultrasound bath for 5 minutes. The swollen resin is moved in a 
reactor, washed 3 times with DCM and filter under vacuum to obtain the dry resin. 
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b) Fmoc Cleavage 
 
 
 
The resin is suspended in a solution of Pip (20% in DMF) and stired for 5 minutes, 
filtered  and the procedure repeated, increasing the stirring time to 15 minutes. After 
that, the resin was filtered and washed 6 times with DMF. The filtered DMF is 
collected in order to quantify the amount of Fmoc cleaved by the deprotection step, 
which is proportional to the amount of aminoacid bound to the resin. 
Measuring the absorbance of the fluorene formed after Fmoc cleavage is possible to 
evaluate the quantity of Fmoc eliminated in the reaction. A sample of the washing 
DMF is dissolved in a known amount of DMF (usually 3 ml) and its UV absorbance 
at 300.8 nm is measured. 
The mol of fluorene are derived from the absorbance using the following formula: 
 
µmol= (abs(Sample)-abs(Blank)) ∙Vs ∙ Vc / (C ∙ Vp) 
 
 Abs(Sample): Sample absorbance at 300,8 nm. 
 Abs(Blank): Blank absorbance at 300,8 nm. 
 Vs: DMF washing volume. 
 Vc: Cuvette volume. 
 Vp: Sample volume. 
 C: Molar extinction coefficient (Cfluorene=7.8 ml/μmol). 
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c) Coupling Reaction 
 
 
 
A solution of Fmoc-AA (3 eq) in TBTU/HOBt (0.45M in DMF, 4 eq) was treated with 
DIEA (8 eq) and added to the resin. The resulting suspension was left shaking for 50 
minutes. Once the reaction is complete, the resin filtered and washed 6 times with 
DMF. 
 
At this stage, if more aminoacids need to be introduced in order to complete the 
sequence, step b) and c) are repeated until the last residue is bound to the resin and 
deprotected. At this point, the resin is washed 3 times with DCM and dried 
thoroughly before proceeding with the peptide cleavage from the resin. 
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 2-Chlorotritylic Resin 
 
 
 
2-Chlorotritylic resin is devoid of protecting group and does not need an activation 
step before the introduction of the first aminoacid.  
 
a) Swelling 
 
The resin is suspended in a solution of NMP (1 ml per 150 µmol of resin) and DCM 
(7.5 ml) and left in a ultrasound bath for 5 minutes. The swollen resin is moved in a 
reactor, washed 3 times with DCM and filter under vacuum to obtain the dry resin. 
 
b) Coupling of the first aminoacid to the resin 
 
 
 
A solution of the Fmoc-AA (150 µmol, 1 eq) in DCM/NMP (2:1, 1 ml) was treated 
with DIEA (2 eq) and added to the resin. The reactor was left shaking for 50 minutes, 
after which 400 µl of MeOH were added in order to cap all the reacting groups left on 
the resin, and the reaction was left shaking for additional 5 minutes. At the end, the 
resin was filtered and washed 6 times with DMF. 
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c) Fmoc Cleavage 
 
 
 
The resin is suspended in a solution of Pip (20% in DMF) and stired for 5 minutes, 
filtered  and the procedure repeated, increasing the stirring time to 15 minutes. After 
that, the resin was filtered and washed 6 times with DMF. The filtered DMF is 
collected in order to quantify the amount of Fmoc cleaved by the deprotection step, 
which is proportional to the amount of aminoacid bound to the resin. 
 
d) Coupling Reaction 
 
 
 
A solution of Fmoc-AA (3 eq) in TBTU/HOBt (0.45M in DMF, 4 eq) was treated with 
DIEA (8 eq) and added to the resin. The resulting suspension was left shaking for 50 
minutes. Once the reaction is complete, the resin filtered and washed 6 times with 
DMF. 
 
At this stage, if more aminoacids need to be introduced in order to complete the 
sequence, step c) and d) are repeated until the last residue is bound to the resin and 
deprotected. At this point, the resin is washed 3 times with DCM and dried 
thoroughly before proceeding with the peptide cleavage from the resin. 
  
 
                                                                                                                                                                               Experimental Section 
  
79 
 
6.3.2 Common Solid-Phase Procedures 
 
a) Ketomethylamine Synthesis 
 
 
A solution of Fmoc-AA (1 eq) in DMF was treated with DIEA (1 eq) and added to the 
resin. The reactor was left shaking overnight. After that, the resin was filtered and 
washed 6 times with DMF. 
 
b) Boc- Protection 
 
 
 
A solution of Boc2O (5 eq) in DCM was treated with DIEA (10 eq) and added to the 
resin. The suspension was left shaking for 1 hour, after which was filtered and 
washed 6 times with DCM. 
 
c) Hydroxyethylamine Synthesis 
 
 
 
The resin was suspended in THF/EtOH (1:1) and treated with 10 mg of NaBH4. After 
4 hours the resin was filtered, washed 3 times with THF, 6 times with THF/ H2O 
(1:1), 2 times with THF and 3 times with MeOH. 
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d) Peptide Cleavage 
 
After removing the N-terminal Fmoc group, the resin was washed 4 times in DCM 
and dried under vacuum. The cleavage cocktail was prepared according to the 
sequence that need to be cleaved and the resin suspended in 3 ml of it for 2 hours, 
after which the liquid was filtered in the chosen precipitation media. The suspension 
created was centrifugated  and the surnatant removed, and new precipitation media 
was added to the precipitate. These operations were repeated two times to remove all 
the cocktail scavengers, after which the precipitate was solubilized in 1 ml of DMSO 
and purified by preparative HPLC. 
 
e) Peptide Purification 
 
Synthesized peptides were purified by reverse-phase HPLC, using a linear gradient 
from H2O/MeOH/TFA 95:5:0.1 to MeOH/TFA 100:0.1 at 14 ml/min. 
Fractions containing the compound were collected, concentrated to remove the 
MeOH, the TFA salt exchanged with HCl (1M) to obtain the hydrochloride salt and 
freeze-dried to remove the water. 
 
6.4  General Synthetic Procedures 
 
a) Diazomethylketone Synthesis 
 
 
 
A solution of Fmoc-AA in anhydrous THF (4.7 ml/mmol of Fmoc-AA) was cooled to 
-15°C and kept under inert atmosphere. Isobutylchloroformate (1.1 eq) and NMM 
(1.1 eq) were added to the solution and the mixture stirred for 15 minutes. The crude 
was then filtered to remove the NMM-salt and the solution cooled to -70°C. The 
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mixture was kept under inert atmosphere, under vigorous stirring, and an excess of 
CH2N2 in Et2O was slowly added dropwise, keeping the reaction below -60°C, and 
the left reacting overnight at 0°C. 
Once completed, the diazomethane excess was evaporated and quenched with 
AcOH, and the crude mixture evaporated under reduced pressure. The crude was 
then solubilized with AcOEt, extracted 3 times with water and 1 time with brine. The 
organic phase was collected, dried over Na2SO4 and evaporated under reduced 
pressure. 
 
b) Bromomethylketone Synthesis 
 
 
 
A solution of Fmoc-diazomethylketone in Et2O (3.5 ml/mmol) was cooled to 0°C and 
HBr 48% (1 eq) was added dropwise. After complete disappearance of the starting 
material (TLC) the reaction was diluted in AcOEt and washed 3 times with a 
saturated solution of NaHCO3, once with water and once with brine. The organic 
phase was collected, dried over Na2SO4 and dried under vacuum. The product was 
used without further purification. 
 
c) Reductive Amination 
 
 
 
A mixture of the chosen aldehyde or ketone (1 eq) and scaffold A or B (1 eq) in 
methanol was left stirring overnight. To this reaction mixture NaBH4 (2 eq) was 
added portion-wise. After 30 minutes the reaction mixture was preadsorbed on C18 
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bonded silica and chromatographed on a semipreparative C18 HPLC column using a 
30 minutes gradient from H2O/MeOH 95:5 to H2O/MeOH (0.1% TFA) 0:100 to give 
the desired product. 
 
d) Coupling Reaction 
 
 
 
A solution of the carboxylic acid (1.1 eq) and the amine (1.0 eq) in an appropriate 
solvent (DMF or dichloromethane) (5mL/mmol), was cooled to 0°C and 
hydroxybenzotriazole (HOBt) (1.5 eq) and O-(benzotriazol-1-yl)-N,N,N′,N′-
tetramethyluronium hexafluorophosphate (HBTU) was added (1.1 eq). NMM was 
added until pH 8 was reached. The mixture was then stirred at room temperature 
overnight. Dichloromethane was then added and the organic phase washed with 
HCl 1N, saturated NaHCO3, water, brine, dried, filtered and concentrated. The crude 
was the purified using normal or reverse phase chromatography. 
 
e) Removal of the Cbz- protecting group 
 
 
 
The Cbz protected compound was dissolved in methanol (10 mL/mmol) and then 
Pd/C (10%) (80 mg/mmol) was added. The mixture was left under H2 atmosphere 
for 2h, checking the progress with TLC after which the mixture was filtrated, washed 
with methanol and the residue concentrated and used in the next step without any 
further purification or characterization. 
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f) Removal of the Boc- protecting group 
 
 
 
Boc protected compound was cooled to 0°C ND HCl 4N in dioxane was added (10 
mL/g of compound). The mixture was stirred at room temperature for 30 minutes, 
after which it was concentrated and the residue washed 3 times with ethyl ether and 
purified using reverse phase HPLC. 
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6.5  Specific Synthetic Procedures 
Compound 1 
 
 
The peptide was synthesized on rink amide resin using SPPS procedure. Cleavage 
for resin was performer using TFA (10 ml), TIS (0.5 ml), thioanisole (0.25 ml) and 
phenol (75 mg), and the peptide precipitated in a solution of Methyl-t-Butyl 
ether/Petroleum ether 1:1. Only one stereoisomer was recovered as a white solid (7.1 
mg, 7.7%). 
 
HRMS-ESI m/z [M+H]+ calcd for C27H53N9O7: 616.4068, found: 616.41392. 
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Compound 2 
 
 
The peptide was synthesized on rink amide resin using SPPS procedure. Cleavage 
for resin was performer using TFA (10 ml), TIS (0.5 ml), thioanisole (0.25 ml) and 
phenol (75 mg), and the peptide precipitated in a solution of Methyl-t-Butyl 
ether/Petroleum ether 1:1. Both stereoisomers were recovered as a white solids (7.0 
mg, 7.7%; 3.4 mg, 3.2%). 
 
HRMS-ESI m/z [M+H]+ calcd for C33H57N9O8: 708.4330, found: 708.44080 and 
707.43929. 
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Compound 3 
 
 
The peptide was synthesized on rink amide resin using SPPS procedure. Cleavage 
for resin was performer using TFA (10 ml), TIS (0.5 ml), thioanisole (0.25 ml) and 
phenol (75 mg), and the peptide precipitated in a solution of Methyl-t-Butyl 
ether/Petroleum ether 1:1. Both stereoisomers were recovered as a white solids (13.3 
mg, 13.7%; 7.2 mg, 7.5%). 
 
HRMS-ESI m/z [M+H]+ calcd for C32H51N7O7: 646.3850, found: 646.39136 and 
646.39127. 
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Compound 4 
 
 
The peptide was synthesized on rink amide resin using SPPS procedure. Cleavage 
for resin was performer using TFA (10 ml), TIS (0.5 ml), thioanisole (0.25 ml) and 
phenol (75 mg), and the peptide precipitated in a solution of Methyl-t-Butyl 
ether/Petroleum ether 1:1. Both stereoisomers were recovered as a white solids (7.3 
mg, 6.6%; 4.6 mg, 3.1%). 
 
HRMS-ESI m/z [M+H]+ calcd for C38H55N7O8: 738.4112, found: 738.41315 and 
738.41421. 
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Compound 5 
 
 
The peptide was synthesized on rink amide resin using SPPS procedure. Cleavage 
for resin was performer using TFA (10 ml), TIS (0.5 ml), thioanisole (0.25 ml) and 
phenol (75 mg), and the peptide precipitated in a solution of Methyl-t-Butyl 
ether/Petroleum ether 1:1. Only one stereoisomer was recovered as a white solid 
(26.7 mg, 28.9%). 
 
HRMS-ESI m/z [M+H]+ calcd for C27H54N10O6: 615.4228, found: 615.43040 and 
615.42946. 
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Compound 6 
 
 
The peptide was synthesized on rink amide resin using SPPS procedure. Cleavage 
for resin was performer using TFA (10 ml), TIS (0.5 ml), thioanisole (0.25 ml) and 
phenol (75 mg), and the peptide precipitated in a solution of Methyl-t-Butyl 
ether/Petroleum ether 1:1. Both stereoisomers were recovered as a white solids (18.5 
mg, 17.5%; 14.2 mg, 13.4%). 
 
HRMS-ESI m/z [M+H]+ calcd for C33H58N10O7: 707.4490, found: 707.45534 and 
707.45536. 
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Compound 7 
 
 
The peptide was synthesized on 2-Chlorotritylic resin using SPPS procedure. 
Cleavage for resin was performer using TFA (10 ml), TIS (0.5 ml), thioanisole (0.25 
ml) and phenol (75 mg), and the peptide precipitated in a solution of Methyl-t-Butyl 
ether/Petroleum ether 1:1. Only one stereoisomer was recovered as a white solid 
(12.8 mg, 15.6%). 
 
HRMS-ESI m/z [M+H]+ calcd for C24H48N8O6: 545.3697, found: 545.37656. 
  
 
                                                                                                                                                                               Experimental Section 
  
91 
 
Compound 8 
 
 
The peptide was synthesized on 2-Chlorotritylic resin using SPPS procedure. 
Cleavage for resin was performer using TFA (10 ml), TIS (0.5 ml), thioanisole (0.25 
ml) and phenol (75 mg), and the peptide precipitated in a solution of Methyl-t-Butyl 
ether/Petroleum ether 1:1. Both stereoisomers were recovered as a white solids (13.8 
mg, 14.5%; 8.8 mg, 9.2%). 
 
HRMS-ESI m/z [M+H]+ calcd for C30H52N8O7: 637.3959, found: 637.40227 and 
637.40285. 
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Compound 9 
 
 
The peptide was synthesized on 2-Chlorotritylic resin using SPPS procedure. 
Cleavage for resin was performer using TFA (10 ml), TIS (0.5 ml), thioanisole (0.25 
ml) and phenol (75 mg), and the peptide precipitated in a solution of Methyl-t-Butyl 
ether/Petroleum ether 1:1. Both stereoisomers were recovered as a white solids (12.3 
mg, 14.1%; 10.3 mg, 11.8%). 
 
HRMS-ESI m/z [M+H]+ calcd for C28H49N7O6: 580.3744, found: 58038127 and 
580.38125. 
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Intermediate 9 
 
 
A mixture of benzylcarbamate (1 g, 6.6 mmol) and Bi(NO3)3 (1.92 g, 3.96 mmol) was 
suspended in cyclohex-2-enone (630 µl, 6.6 mmol) and stirred overnight at room 
temperature. After complete consumption of the starting material (TLC 
chromatography), the mixture is diluted using DCM and filtered to remove the 
catalyst. The filtrated solution was then concentrated under pressure, followed by 
flash chromatography (Cyclohexene/AcOEt  100:0 to 50:50). Intermediate 9 was 
isolated as an orange solid (1.46 g, 5.97 mmol, 90.4%). 
 
Rf=0.44 (Cyclohexane/AcOEt 5:5) 
 
1H NMR (500 MHz, CDCl3) δ=7.39 – 7.30 (m, 5H), 5.09 (s, 1H), 4.77 (s, 1H), 3.99 (s, 
1H), 2.70 (dt, J = 17.2, 8.6 Hz, 1H), 2.41 – 2.34 (m, 1H), 2.31 – 2.22 (m, 2H), 2.15 – 2.06 
(m, 1H), 2.02 – 1.93 (m, 1H), 1.83 – 1.55 (m, 1H). 
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Intermediate 10 and 11 
 
A solution of intermediate 9 (1.46 g, 5.97 mmol) in dry toluene over 3Å molecular 
sieves (0.3 g/mmol) was treated with allylamine (1.3 ml, 17.91 mmol) and 
allylboronic acid pinacol ester (5.6 ml, 29.85 mmol) and stirred overnight at 80°C. The 
reaction crude was then filtered to remove the molecular sieves and concentrated 
under vacuum, followed by flash chromatography (Cyclohexane/AcOEt 100:0 to 
50:50). It was possible to separate the two diastereoisomer 10 (0.95 g, 3.02 mmol) and 
11 (0.51 mg, 1.61 mmol) as dark yellow oils due to their different retention (Rf= 0.67 
and Rf=0.32 in cyclohexane/AcOEt 7:3). The overall yield of the reaction was 77.5%.  
 
1H NMR of 10 (500 MHz, [D6]DMSO) δ=8.37 (s, 1H), 7.50 – 7.20 (m, 5H), 6.01 – 5.91 
(m, 1H), 5.79 (td, J = 17.2, 7.3 Hz, 1H), 5.50 (d, J = 17.0 Hz, 1H), 5.41 (d, J = 10.2 Hz, 
1H), 5.24 (d, J = 7.2 Hz, 1H), 5.21 (s, 1H), 5.03 (s, 2H), 3.83 – 3.72 (m, 2H), 3.64 (s, 1H), 
2.45 (d, J = 7.2 Hz, 2H), 2.00 (d, J = 14.0 Hz, 1H), 1.86 – 1.75 (m, 2H), 1.71 – 1.60 (m, 
2H), 1.49 – 1.37 (m, 2H), 1.19 – 1.10 (m, 1H). 
 
1H NMR of 11 (500 MHz, [D6]DMSO) δ=8.56 (d, J = 27.9 Hz, 1H), 7.46 – 7.26 (m, 5H), 
5.95 – 5.75 (m, 2H), 5.49 (d, J = 17.1 Hz, 1H), 5.37 (t, J = 14.2 Hz, 2H), 5.27 (d, J = 9.8 
Hz, 1H), 5.02 (s, 2H), 3.60 (s, 2H), 3.56 – 3.48 (m, 1H), 2.65 – 2.52 (m, 2H), 2.11 (d, J = 
11.7 Hz, 1H), 1.90 – 1.76 (m, 2H), 1.74 – 1.65 (m, 1H), 1.56 – 1.32 (m, 3H), 1.25 – 1.06 
(m, 1H). 
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Intermediate 12  
 
 
A solution of intermediate 10 (1.75 g, 5.56 mmol) in dry THF was cooled at -78°C and 
treated with NaH (0.67 g, 27.8 mmol). After the solution had been stirred for 30 min 
at -78°C the reaction was brought to room temperature and methylchloroformate 
was added dropwise (2.15 ml, 27.8 mmol) and left reacting overnight. At the end of 
the reaction (TLC chromatography) the crude was diluted with DCM and quenched 
with HCl 1M. The organic layer was separated and extracted three times with HCl 
1M, once with brine and then collected, dried (NaSO4) and evaporated under 
vacuum. The residue was purified by flash chromatography (Cyclohexane/AcOEt 
100:0 to 80:20) to give intermediate 12 (1.56 g, 4.04 mmol, 72.6%) as a yellow oil. 
 
Rf=0.57 (Cyclohexane/AcOEt 7:3). 
 
1H NMR (500 MHz, [D6]DMSO) δ=7.42 – 7.25 (m, 5H), 7.17 (d, J = 6.5 Hz, 1H), 5.93 – 
5.80 (m, 1H), 5.79 – 5.66 (m, 1H), 5.18 (d, J = 17.2 Hz, 1H), 5.10 – 4.93 (m, 6H), 4.02 – 
3.91 (m, 2H), 3.55 (s, 3H), 3.47 – 3.38 (m, 1H), 2.70 – 2.61 (m, 1H), 2.41 (d, J = 6.9 Hz, 
2H), 1.78 (d, J = 10.5 Hz, 1H), 1.53 (d, J = 13.2 Hz, 1H), 1.39 – 1.26 (m, 1H), 1.25 – 1.04 
(m, 3H). 
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Intermediate 14 
 
 
To a solution of intermediate 12 (1.56 g, 6.04 mmol) in DCM was added 1% of 1st 
generation Grubbs catalyst and left stirring at 60°C overnight. After complete 
consumption of the reagent (TLC chromatography) the reaction mixture was diluted 
and filtered to eliminate the catalyst, then concentrated under vacuum. Flash 
chromatography (Cyclohexane/AcOEt 100:0 to 70:30) gave intermediate 14 (1.31 g, 
3.65 mmol, 91.0%) as a yellow oil. 
 
Rf=0.42 (Cyclohexane/AcOEt 7:3) 
 
1H NMR (500 MHz, [D6]DMSO) δ=7.43 – 7.26 (m, 5H), 7.18 (d, J = 7.2 Hz, 1H), 5.66 (q, 
J = 10.8 Hz, 2H), 5.00 (s, 2H), 4.11 (d, J = 18.6 Hz, 1H), 3.98 (d, J = 18.6 Hz, 1H), 3.55 (s, 
3H), 3.45 – 3.34 (m, 1H), 2.74 (d, J = 13.2 Hz, 1H), 2.59 (d, J = 13.2 Hz, 1H), 2.15 (d, J = 
17.4 Hz, 1H), 1.91 (d, J = 17.4 Hz, 1H), 1.81 (d, J = 11.6 Hz, 1H), 1.56 (d, J = 13.3 Hz, 
1H), 1.39 (dd, J = 26.6, 13.3 Hz, 1H), 1.21 (ddd, J = 25.1, 12.3, 4.1 Hz, 1H), 1.06 (t, J = 
12.4 Hz, 1H), 0.99 (t, J = 12.4 Hz, 1H). 
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Scaffold A 
 
 
Pd/C (10 wt.%, 31.3 mg) was added to a solution of intermediate 14 (1.40 g, 3.91 
mmol) in isopropanol (3.9 ml) with catalytic amount of TFA (25 µl). After three cycles 
of vacuum/H2, the solution is kept under vigorous stirring in an atmosphere of H2 
until the complete disappearance of the starting material was observed in TLC 
(DCM/MeOH 9:1). The crude was then filtered to remove the catalyst and 
concentrated under vacuum. Flash chromatography (DCM/MeOH/NH3 99:1:0.1 to 
90:10:0.1) gave scaffold A (873.6 mg, 3.86 mmol, 98.7%) as an highly hygroscopic 
solid. 
 
Rf=0.13 (DCM/MeOH/NH3 9:1:0.1). 
 
1H NMR (500 MHz, [D6]DMSO) δ=7.87 (bs, 2H), 3.62 – 3.53 (m, 4H), 3.38 – 3.29 (m, 
1H), 3.16 – 3.05 (m, 1H), 3.01 (d, J = 13.1 Hz, 1H), 2.72 (d, J = 12.7 Hz, 1H), 1.98 – 1.88 
(m, J = 12.1 Hz, 1H), 1.76 – 1.65 (m, 1H), 1.65 – 1.56 (m, 2H), 1.47 (t, J = 6.1 Hz, 2H), 
1.44 – 1.38 (m, 1H), 1.38 – 1.23 (m, 3H), 1.13 (t, J = 12.5 Hz, 1H), 0.93 (td, J = 13.7, 2.7 
Hz, 1H).  
 
HRMS-ESI m/z [M+H]+ calcd for C12H23N2O2: 227,175585, found: 227,175404 
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Intermediate 13  
 
 
A solution of intermediate 11 (0.66 g, 2.01 mmol) in dry THF was cooled at -78°C and 
treated with NaH (0.24 g, 10.05 mmol). After the solution had been stirred for 30 min 
at -78°C the reaction was brought to room temperature and methylchloroformate 
was added dropwise (0.77 ml, 10.05 mmol) and left reacting overnight. At the end of 
the reaction (TLC chromatography) the crude was diluted with DCM and quenched 
with HCl 1M. The organic layer was separated and extracted three times with HCl 
1M,  once with brine and then collected, dried (NaSO4) and evaporated under 
vacuum. The residue was purified by flash chromatography (Cyclohexane/AcOEt 
100:0 to 50:50) to give intermediate 13 (0.53 g, 1.36 mmol, 67.8%) as a yellow oil. 
 
Rf=0.57 (Cyclohexane/AcOEt 7:3). 
 
1H NMR (300 MHz, CDCl3) δ=7.40 – 7.31 (m, 5H), 5.84 – 5.63 (m, 1H), 5.30 (s, 1H), 
5.15 – 5.02 (m, 4H), 4.57 (d, J = 8.2 Hz, 1H), 3.92 – 3.85 (m, 2H), 3.65 (s, 3H), 2.81 – 2.64 
(m, 3H), 2.42 – 2.32 (m, 1H), 2.01 (d, J = 12.4 Hz, 1H), 1.74 – 1.59 (m, 4H), 1.50 – 1.34 
(m, 1H), 1.34 – 1.21 (m, 2H), 1.06 – 0.95 (m, 1H). 
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Intermediate 15 
 
 
To a solution of intermediate 13 (1.26 g, 3.25 mmol) in DCM was added 1% of 1st 
generation Grubbs catalyst and left stirring at 60°C overnight. After complete 
consumption of the reagent (TLC chromatography) the reaction mixture was diluted 
and filtered to eliminate the catalyst, then concentrated under vacuum. Flash 
chromatography (Cyclohexane/AcOEt 100:0 to 50:50) gave intermediate 15 (0.99 g, 
2.76 mmol, 84.9%) as a yellow oil. 
 
Rf=0.38 (Cyclohexane/AcOEt 7:3). 
 
1H NMR (300 MHz, CDCl3) δ=7.39 – 7.28 (m, 5H), 5.92 – 5.77 (m, 1H), 5.07 (s, 1H), 
4.75 – 4.64 (m, 1H), 3.96 (s, 2H), 3.62 (s, 3H), 2.35 – 2.27 (m, 2H), 2.27 – 2.16 (m, 1H), 
2.13 – 2.03 (m, 2H), 1.95 (d, J = 13.2 Hz, 1H), 1.80 – 1.60 (m, 2H), 1.51 – 1.32 (m, 3H), 
1.26 – 1.06 (m, 2H). 
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Scaffold B 
 
 
Pd/C (10 wt.%, 0.17 mg) was added to a solution of intermediate 15 (0.75 g, 2.11 
mmol) in isopropanol (20 ml) with catalytic amount of TFA (25 µl). After three cycles 
of vacuum/H2, the solution is kept under vigorous stirring in an atmosphere of H2 
until the complete disappearance of the starting material was observed in TLC 
(DCM/MeOH 9:1). The crude was then filtered to remove the catalyst and 
concentrated under vacuum. Flash chromatography (DCM/MeOH/NH3 99:1:0.1 to 
90:10:0.1) gave scaffold B (0.33 g, 1.44 mmol, 68.3%) as an highly hygroscopic solid. 
 
Rf=0.13 (DCM/MeOH/NH3 9:1:0.1). 
 
1H NMR (300 MHz, CDCl3) δ=3.67 (d, J = 8.7 Hz, 2H), 3.61 (s, 3H), 3.43 (d, J = 13.8 
Hz, 2H), 3.22 (s, 1H), 2.70 (t, J = 12.2 Hz, 1H), 2.32 (d, J = 9.8 Hz, 2H), 2.07 (d, J = 10.9 
Hz, 2H), 1.66 (d, J = 23.4 Hz, 4H), 1.38 (s, 2H), 1.25 (s, 1H), 1.15 (d, J = 6.2 Hz, 2H). 
 
HRMS-ESI m/z [M+H]+ calcd for C12H23N2O2: 227,175585, found: 227,175965. 
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Compound 10 
 
 
Compound 10 was prepared according to general procedure by reacting  (−)-
myrtenal (33.0 mg, 0.22 mmol) with A (50 mg, 0.22 mmol). Compound 10 was 
isolated as a light yellow oil (14 mg, 0.04 mmol, 18.2%). 
 
Rf=0.44 (DCM/MeOH 9:1). 
 
1H NMR (500 MHz, CD3OD) δ=5.79 (s, 1H), 3.87 – 3.77 (m, 1H), 3.65 (s, 4H), 3.58 (s, 
1H), 3.52 (d, J = 14.3 Hz, 1H), 3.38 – 3.32 (m, 1H), 3.28 – 3.21 (m, 1H), 2.77 (d, J = 14.5 
Hz, 1H), 2.55 – 2.47 (m, 1H), 2.36 (d, J = 9.8 Hz, 2H), 2.27 – 2.21 (m, 1H), 2.14 (s, 2H), 
1.89 – 1.72 (m, 3H), 1.72 – 1.60 (m, 2H), 1.59 – 1.38 (m, 4H), 1.35 (s, 2H), 1.23 (dd, J = 
8.9, 2.5 Hz, 1H), 1.01 (t, J = 12.9 Hz, 1H), 0.92 – 0.84 (m, 6H). 
 
HRMS-ESI m/z [M+H]+ calcd for C22H37N2O2: 361.284955, found: 361.283845. 
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Compound 11 
 
 
Compound 11 was prepared according to general procedure by reacting 2-
bromobenzaldehyde (40.7 mg, 0.22 mmol) with A (50 mg, 0.22 mmol). Compound 11 
was isolated as a orange oil (83 mg, 0.21 mmol, 94.5%). 
 
Rf=0.50 (DCM/MeOH 9:1). 
 
1H NMR (600 MHz, CD3OD) δ=7.74 (dd, J = 7.4, 4.1 Hz, 1H), 7.62 (dd, J = 7.6, 1.4 Hz, 
1H), 7.48 (t, J = 7.5 Hz, 1H), 7.38 (td, J = 7.9, 1.5 Hz, 1H), 4.48 (t, J = 11.2 Hz, 1H), 4.40 
(t, J = 11.6 Hz, 1H), 3.90 (t, J = 3.7 Hz, 1H), 3.88 (t, J = 3.7 Hz, 1H), 3.67 (s, 3H), 3.59 – 
3.52 (m, 1H), 3.48 (dd, J = 12.6, 2.5 Hz, 1H), 3.26 – 3.20 (m, 1H), 2.82 – 2.75 (m, 1H), 
2.24 (d, J = 10.7 Hz, 1H), 1.92 – 1.78 (m, 3H), 1.69 (m, 2H), 1.60 – 1.52 (m, 3H), 1.52 – 
1.45 (m, 2H), 1.36 (t, J = 12.3 Hz, 1H). 
 
HRMS-ESI m/z [M+H]+ calcd for C19H28BrN2O2: 395.132867, found: 395.134011. 
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Compound 12 
 
 
Compound 14 was prepared according to general procedure by reacting 3-
bromobenzaldehyde (40.7 mg, 0.22 mmol) with A (50 mg, 0.22 mmol). Compound 14 
was isolated as a orange oil (82 mg, 0.21 mmol, 94.5%). 
 
Rf=0.50 (DCM/MeOH 9:1). 
 
1H NMR (600 MHz, CD3OD) δ=7.74 (s, J = 8.7 Hz, 1H), 7.61 (d, J = 8.0 Hz, 1H), 7.48 
(d, J = 7.7 Hz, 1H), 7.38 (t, J = 7.9 Hz, 1H), 4.27 (t, J = 13.4 Hz, 1H), 4.20 (d, J = 13.3 Hz, 
1H), 3.90 – 3.80 (m, 1H), 3.65 (s, 3H), 3.45 (tt, J = 13.8, 4.6, 3.0 Hz, 1H), 3.40 (dd, J = 
12.6, 2.5 Hz, 1H), 3.22 (ddd, J = 14.5, 11.5, 2.9 Hz, 1H), 3.00 (s, 1H), 2.77 (dd, J = 14.7, 
2.3 Hz, 1H), 2.16 (t, J = 16.7 Hz, 1H), 1.91 – 1.81 (m, 1H), 1.81 – 1.75 (m, 1H), 1.71 – 
1.62 (m, 2H), 1.60 – 1.51 (m, 2H), 1.50 – 1.37 (m, 3H), 1.30 (t, J = 12.3 Hz, 1H), 1.08 – 
0.99 (m, 1H). 
 
HRMS-ESI m/z [M+H]+ calcd for C19H28BrN2O2: 395.132867, found: 395.132189. 
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Compound 13 
 
 
Compound 13 was prepared according to general procedure by reacting 4-
bromobenzaldehyde (40.7 mg, 0.22 mmol) with A (50 mg, 0.22 mmol). Compound 13 
was isolated as a orange oil (78 mg, 0.20 mmol, 90.9%). 
 
Rf=0.35 (DCM/MeOH 9:1). 
 
1H NMR (300 MHz, CDCl3) δ=7.58 (d, J = 8.6 Hz, 2H), 7.10 (d, J = 8.6 Hz, 2H), 3.82 (s, 
2H), 3.61 (s, 3H), 3.11 (d, J = 12.4 Hz, 1H), 2.91 (d, J = 22.1 Hz, 2H), 2.68 (d, J = 12.1 
Hz, 1H), 2.33 – 2.22 (m, 1H), 2.06 – 1.80 (m, 4H), 1.70 – 1.53 (m, 2H), 1.52 – 1.39 (m, 
1H), 1.11 – 0.94 (m, 2H), 0.92 – 0.76 (m, 4H). 
 
RMS-ESI m/z [M+H]+ calcd for C19H28BrN2O2: 395.132867, found: 395.13285. 
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Compound 14 
 
 
Compound 14 was prepared according to general procedure by reacting 
isovaleraldehyde (23.2 mg, 0.27 mmol) with A (60.0 mg, 0.27 mmol). Compound 14 
was isolated as a light yellow oil (61.4 mg, 0.21 mmol, 77.8%). 
 
Rf=0.25 (DCM/MeOH 9:1). 
 
1H NMR (300 MHz, CDCl3) δ=3.26 (s, 3H), 3.23 – 3.16 (m, 1H), 3.12 – 3.00 (m, 2H), 
2.64 – 2.54 (m, 2H), 2.44 – 2.32 (m, 2H), 2.32 – 2.26 (m, 2H), 1.64 – 1.52 (m, 1H), 1.37 – 
1.19 (m, 4H), 1.18 – 1.05 (m, 4H), 1.00 (dt, J = 8.2, 6.4 Hz, 2H), 0.78 – 0.56 (m, 3H), 0.53 
(s, 3H), 0.51 (s, 3H). 
 
HRMS-ESI m/z [M+H]+ calcd for C17H33N2O2: 297.253655, found: 297.253655. 
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Compound 15 
 
 
Compound 15 was prepared according to general procedure by reacting 
benzaldehyde (20 mg, 0.088 mmol) with A (9.35 mg, 0.088 mmol). Compound 15 was 
isolated as a yellow oil (20 mg, 0.063 mmol, 71.6%). 
 
Rf=0.43 (DCM/MeOH 9:1). 
 
1H NMR (600 MHz, [D6]DMSO) δ=7.49 (d, J = 7.0 Hz, 2H), 7.46 – 7.37 (m, 1H), 4.24 – 
4.17 (m, 1H), 4.16 – 4.09 (m, 1H), 3.56 – 3.49 (m, 4H), 3.35 – 3.29 (m, 1H), 3.20 – 3.13 
(m, 1H), 2.72 (d, J = 14.1 Hz, 1H), 2.13 – 2.08 (m, 1H), 2.06 (s, 2H), 1.80 – 1.56 (m, 4H), 
1.53 – 1.26 (m, 6H), 1.20 (t, J = 13.0 Hz, 1H), 1.00 – 0.90 (m, 1H). 
 
 HRMS-ESI m/z [M+H]+ calcd for C19H29N2O2: 317.222355, found: 317.222713. 
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Compound 16 
 
 
Compound 16 was prepared according to general procedure by reacting adamantan-
2-one (81.1 mg, 0.27 mmol) with A (60.0 mg, 0.27 mmol). Compound 16 was isolated 
as a light yellow oil (60.0 mg, 0.17 mmol, 61.6%). 
 
Rf=0.40 (DCM/MeOH 9:1). 
 
1H NMR (300 MHz, CDCl3) δ=3.72 (dt, J = 14.3, 4.5 Hz, 1H), 3.55 (s, 3H), 3.47 (s, 1H), 
3.45 – 3.26 (m, 2H), 3.23 – 3.13 (m, 2H), 2.62 (d, J = 14.2 Hz, 1H), 2.40 – 2.22 (m, 3H), 
2.28 – 2.07 (m, 2H), 1.94 – 1.81 (m, 3H), 1.81 – 1.60 (m, 6H), 1.60 – 1.46 (m, 5H), 1.47 – 
1.33 (m, 3H), 1.21 – 1.15 (m, 2H), 1.09 – 0.97 (m, 2H). 
 
LRMS-ESI m/z [M+H]+ calcd for C22H37N2O2: 361.28, found: 361.43. 
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Compound 17 
 
 
Compound 17 was prepared according to general procedure by reacting 4-
phenoxybenzaldehyde (53.5 mg, 0.27 mmol) with A (60 mg, 0.27 mmol). Compound 
17 was isolated as a yellow oil (81.3 mg, 0.20 mmol, 74.1%). 
 
Rf=0.38 (DCM/MeOH 9:1). 
 
1H NMR (600 MHz, [D6]DMSO) δ=8.71 (s, 1H), 7.52 (d, J = 8.6 Hz, 2H), 7.44 – 7.40 (m, 
2H), 7.18 (t, J = 7.4 Hz, 1H), 7.07 (d, J = 8.6 Hz, 1H), 7.02 (dd, J = 8.6, 1.0 Hz, 1H), 4.24 
– 4.16 (m, 1H), 4.16 – 4.08 (m, 1H), 3.59 – 3.52 (m, 4H), 3.32 – 3.29 (m, 1H), 3.19 (d, J = 
10.9 Hz, 2H), 2.74 (d, J = 14.1 Hz, 1H), 2.12 (s, 1H), 1.74 – 1.59 (m, 4H), 1.52 – 1.30 (m, 
7H), 1.21 (t, J = 13.0 Hz, 1H), 0.98 (dd, J = 18.7, 8.0 Hz, 1H). 
 
HRMS-ESI m/z [M+H]+ calcd for C25H33N2O3: 409.248569, found: 409.249469. 
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Compound 18 
 
 
Compound 18 was prepared according to general procedure by reacting 2,4 
dimethoxybenzaldehyde (44.9 mg, 0.27 mmol) with A (60 mg, 0.27 mmol). 
Compound 18 was isolated as a yellow oil (67 mg, 0.18 mmol, 66.7%). 
 
Rf=0.42 (DCM/MeOH 9:1). 
 
1H NMR (600 MHz, CD3OD) δ=7.29 (d, J = 8.3 Hz, 1H), 6.62 (d, J = 2.3 Hz, 1H), 6.56 
(dd, J = 8.3, 2.3 Hz, 1H), 4.19 (t, J = 13.0 Hz, 1H), 4.12 (t, J = 13.5 Hz, 1H), 3.90 (s, 3H), 
3.84 (t, J = 3.9 Hz, 1H), 3.82 (s, J = 2.7 Hz, 3H), 3.64 (s, 3H), 3.40 – 3.33 (m, 2H), 3.27 – 
3.18 (m, 1H), 2.79 – 2.72 (m, 1H), 2.19 – 2.13 (m, 1H), 1.89 – 1.74 (m, 3H), 1.70 – 1.61 
(m, 2H), 1.59 – 1.49 (m, 2H), 1.49 – 1.40 (m, 3H), 1.30 (t, J = 12.9 Hz, 1H), 1.05 – 0.97 
(m, 1H). 
 
HRMS-ESI m/z [M+H]+ calcd for C21H33N2O4: 377.243484, found: 377.243882. 
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Compound 19 
 
 
Compound 19 was prepared according to general procedure by reacting 2-
naphthaldehyde (42.2 mg, 0.27 mmol) with A (60 mg, 0.27 mmol). Compound 19 was 
isolated as a yellow oil (49 mg, 0.13 mmol, 49.5%). 
 
Rf=0.37 (DCM/MeOH 9:1). 
 
1H NMR (300 MHz, CDCl3) δ=7.88 – 7.72 (m, 4H), 7.54 – 7.36 (m, 3H), 4.01 (s, 2H), 
3.70 – 3.49 (m, 4H), 3.45 – 3.30 (m, 2H), 3.10 (d, J = 15.9 Hz, 1H), 2.91 – 2.64 (m, 2H), 
2.01 (d, J = 13.9 Hz, 1H), 1.86 – 1.30 (m, 7H), 1.28 – 1.07 (m, 1H), 1.05 – 0.89 (m, 2H). 
 
HRMS-ESI m/z [M+H]+ calcd for C23H31N2O2: 367.238005, found: 367.237119. 
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Compound 20 
 
 
Compound 20 was prepared according to general procedure by reacting (−)-
myrtenal (19.5 mg, 0.13 mmol) with B (30 mg, 0.13 mmol). Compound 20 was 
isolated as a light yellow oil (5 mg, 0.013 mmol, 10%). 
 
Rf=0.40 (DCM/MeOH 9:1). 
 
1H NMR (300 MHz, CDCl3) δ=5.34 (t, J = 4.9 Hz, 1H), 3.71 – 3.66 (m, 1H), 3.62 (s, 3H), 
3.54 – 3.47 (m, 2H), 3.12 (s, 2H), 2.61 – 2.40 (m, 2H), 2.40 – 2.31 (m, 2H), 2.29 – 2.19 (m, 
2H), 2.07 (d, J = 5.2 Hz, 1H), 1.97 – 1.81 (m, 2H), 1.76 – 1.64 (m, 3H), 1.27 (s, 2H), 1.25 
(s, 3H), 1.17 – 1.11 (m, 3H), 0.94 – 0.85 (m, 4H), 0.82 (s, 3H). 
 
HRMS-ESI m/z [M+H]+ calcd for C22H37N2O2: 361.284955, found: 361.285951. 
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Compound 21 
 
 
Compound 21 was prepared according to general procedure by reacting 2-
bromobenzaldehyde (24.0 mg, 0.13 mmol) with B (30 mg, 0.13 mmol). Compound 21 
was isolated as a orange oil (4 mg, 0.010 mmol, 3.85%). 
 
Rf=0.50 (DCM/MeOH 9:1). 
 
1H NMR (300 MHz, CDCl3) δ=7.52 (d, J = 7.9 Hz, 1H), 7.42 (d, J = 7.6 Hz, 1H), 7.31 – 
7.27 (m, 1H), 7.15 – 7.07 (m, 1H), 3.88 (d, J = 3.7 Hz, 2H), 3.70 (t, J = 4.1 Hz, 1H), 3.63 
(s, 3H), 3.52 (dd, J = 9.0, 2.9 Hz, 2H), 2.70 – 2.54 (m, 2H), 2.49 (dd, J = 13.3, 4.5 Hz, 1H), 
2.35 (t, J = 12.1 Hz, 1H), 2.06 – 1.91 (m, 1H), 1.73 – 1.51 (m, 5H), 1.41 – 1.04 (m, 4H), 
0.92 – 0.79 (m, 1H). 
 
HRMS-ESI m/z [M+H]+ calcd for C19H28BrN2O2: 395.132867, found: 395.132867. 
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Compound 22 
 
 
Compound 22 was prepared according to general procedure by reacting 3-
bromobenzaldehyde (24.0 mg, 0.13 mmol) with B (30 mg, 0.13 mmol). Compound 22 
was isolated as a orange oil (20 mg, 0.05 mmol, 38.5%). 
 
Rf=0.50 (DCM/MeOH 9:1). 
 
1H NMR (300 MHz, CDCl3) δ=7.51 (d, J = 14.3 Hz, 1H), 7.36 (d, J = 7.6 Hz, 1H), 7.23 – 
7.12 (m, 2H), 3.79 (s, 2H), 3.72 – 3.68 (m, 1H), 3.63 (s, 2H), 3.55 – 3.48 (m, 2H), 2.66 – 
2.41 (m, 2H), 2.38 – 2.25 (m, 1H), 2.06 – 1.86 (m, 3H), 1.74 – 1.49 (m, 4H), 1.38 – 1.17 
(m, 4H), 0.86 (dd, J = 14.7, 7.5 Hz, 2H). 
 
HRMS-ESI m/z [M+H]+ calcd for C19H28BrN2O2: 395.132867, found: 395.133935. 
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Compound 23 
 
 
Compound 23 was prepared according to general procedure by reacting 4-
bromobenzaldehyde (24.0 mg, 0.13 mmol) with B (30 mg, 0.13 mmol). Compound 23 
was isolated as a orange oil (5.7 mg, 0.014 mmol, 10.8%). 
 
Rf=0.33 (DCM/MeOH 9:1). 
 
1H NMR (300 MHz, CDCl3) δ=7.45 – 7.39 (m, 2H), 7.22 – 7.17 (m, 2H), 3.77 (s, 2H), 
3.71 – 3.68 (m, 1H), 3.63 (s, 3H), 3.54 – 3.48 (m, 2H), 2.67 – 2.43 (m, 2H), 2.38 – 2.25 (m, 
2H), 2.00 – 1.86 (m, 1H), 1.74 – 1.58 (m, 4H), 1.38 – 1.15 (m, 3H), 1.15 – 0.99 (m, 2H), 
0.94 – 0.79 (m, 1H). 
 
HRMS-ESI m/z [M+H]+ calcd for C19H28BrN2O2: 395.132867, found: 395.132896. 
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Compound 24 
 
 
Compound 24 was prepared according to general procedure by reacting 
isovaleraldehyde (11.2 mg, 0.13 mmol) with B (30.0 mg, 0.13 mmol). Compound 24 
was isolated as a light yellow oil (9.0 mg, 0.037 mmol, 23.1%). 
 
Rf=0.40 (DCM/MeOH 9:1). 
 
1H NMR (300 MHz, CDCl3) δ=3.69 (t, J = 4.2 Hz, 3H), 3.62 (s, 3H), 3.51 (d, J = 10.0 Hz, 
2H), 2.67 – 2.55 (m, 2H), 2.55 – 2.46 (m, 1H), 2.29 (dd, J = 26.0, 12.1 Hz, 1H), 2.09 – 1.82 
(m, 3H), 1.77 – 1.45 (m, 5H), 1.42 – 1.12 (m, 4H), 1.07 – 0.93 (m, 3H), 0.90 (s, 2H), 0.87 
(s, 3H). 
 
HRMS-ESI m/z [M+H]+ calcd for C17H33N2O2: 297.253655, found: 297.253632. 
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Compound 25 
 
 
Compound 25 was prepared according to general procedure by reacting 
benzaldehyde (13.8 mg, 0.13 mmol) with B (30.0 mg, 0.13 mmol). Compound 25 was 
isolated as a yellow oil (2 mg, 0.006 mmol, 4.9%). 
 
Rf=0.25 (DCM/MeOH 9:1). 
 
1H NMR (300 MHz, CDCl3) δ=7.32 (d, J = 5.9 Hz, 3H), 7.26 (d, J = 18.2 Hz, 2H), 3.84 (s, 
2H), 3.63 (s, 3H), 3.54 – 3.49 (m, 1H), 2.73 – 2.58 (m, 1H), 2.57 – 2.43 (m, 1H), 2.37 (t, J 
= 12.0 Hz, 1H), 1.99 (d, J = 8.5 Hz, 1H), 1.90 – 1.71 (m, 2H), 1.72 – 1.46 (m, 4H), 1.44 – 
1.20 (m, 3H), 1.18 – 1.04 (m, 2H), 0.94 – 0.79 (m, 2H). 
 
HRMS-ESI m/z [M+H]+ calcd for C19H29N2O2: 317.222355, found: 317.222198. 
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Compound 26 
 
 
Compound 26 was prepared according to general procedure by reacting adamantan-
2-one (20.0 mg, 0.13 mmol) with B (30.0 mg, 0.13 mmol). Compound 26 was isolated 
as a light yellow oil (5.5 mg, 0.015 mmol, 11.5%). 
 
Rf=0.40 (DCM/MeOH 9:1). 
 
1H NMR (300 MHz, CDCl3) δ 3.85 (s, 1H), 3.69 (d, J = 8.1 Hz, 1H), 3.63 (s, J = 10.9 Hz, 
3H), 3.52 (s, 2H), 3.09 – 2.78 (m, 2H), 2.64 (d, J = 11.8 Hz, 1H), 2.61 – 2.35 (m, 3H), 2.17 
– 1.91 (m, 4H), 1.89 – 1.76 (m, J = 22.8 Hz, 5H), 1.78 – 1.46 (m, 6H), 1.39 – 1.10 (m, 6H), 
0.92 – 0.78 (m, 2H). 
 
HRMS-ESI m/z [M+H]+ calcd for C22H37N2O2: 361.284955, found: 361.285308. 
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Compound 27 
 
 
Compound 27 was prepared according to general procedure by reacting 4-
phenoxybenzaldehyde (13.9 mg, 0.07 mmol) with B (15 mg, 0.07 mmol). Compound 
27 was isolated as a yellow oil (5.5 mg, 0.013 mmol, 18.6%). 
 
Rf=0.50 (DCM/MeOH 9:1). 
 
1H NMR (600 MHz, [D6]DMSO) δ=8.71 (s, 1H), 7.52 (d, J = 8.6 Hz, 2H), 7.44 – 7.40 (m, 
2H), 7.18 (t, J = 7.4 Hz, 1H), 7.07 (d, J = 8.6 Hz, 1H), 7.02 (dd, J = 8.6, 1.0 Hz, 1H), 4.24 
– 4.16 (m, 1H), 4.16 – 4.08 (m, 1H), 3.59 – 3.52 (m, 4H), 3.32 – 3.29 (m, 1H), 3.19 (d, J = 
10.9 Hz, 2H), 2.74 (d, J = 14.1 Hz, 1H), 2.12 (s, 1H), 1.74 – 1.59 (m, 4H), 1.52 – 1.30 (m, 
7H), 1.21 (t, J = 13.0 Hz, 1H), 0.98 (dd, J = 18.7, 8.0 Hz, 1H). 
 
LRMS-ESI m/z [M+H]+ calcd for C25H33N2O3: 409.25, found: 409.24. 
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Compound 28 
 
 
Compound 28 was prepared according to general procedure by reacting 2,4 
dimethoxybenzaldehyde (22.0 mg, 0.13 mmol) with B (30 mg, 0.13 mmol). 
Compound 28 was isolated as a yellow oil (6.4 mg, 0.017 mmol, 13.1%). 
 
Rf=0.25 (DCM/MeOH 9:1). 
 
1H NMR (300 MHz, CDCl3) δ=7.17 (d, J = 8.9 Hz, 1H), 6.43 (d, J = 5.9 Hz, 1H), 6.41 (d, 
J = 2.2 Hz, 1H), 3.81 (s, J = 3.7 Hz, 3H), 3.79 (s, J = 3.6 Hz, 3H), 3.78 – 3.73 (m, 2H), 3.73 
– 3.66 (m, 1H), 3.63 (s, 3H), 3.57 – 3.45 (m, 2H), 2.74 – 2.57 (m, 1H), 2.50 (td, J = 13.2, 
4.5 Hz, 1H), 2.41 – 2.26 (m, 1H), 2.13 – 1.77 (m, 3H), 1.74 – 1.47 (m, 4H), 1.46 – 1.02 (m, 
3H), 0.95 – 0.76 (m, 2H). 
 
HRMS-ESI m/z [M+H]+ calcd for C21H33N2O4: 377.243484, found: 377.243739. 
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Compound 29 
 
 
Compound 29 was prepared according to general procedure by reacting 2-
naphthaldehyde (20.3 mg, 0.13 mmol) with B (30 mg, 0.13 mmol). Compound 29 was 
isolated as a yellow oil (2.6 mg, 0.007 mmol, 5.4%). 
 
Rf=0.38 (DCM/MeOH 9:1). 
 
1H NMR (300 MHz, CDCl3) δ=7.87 – 7.72 (m, 4H), 7.52 – 7.38 (m, 3H), 4.00 (s, 2H), 
3.64 (s, 3H), 3.52 (t, J = 5.8 Hz, 2H), 2.68 (t, J = 11.2 Hz, 1H), 2.56 – 2.45 (m, 1H), 2.39 (t, 
J = 12.0 Hz, 1H), 2.01 (t, J = 10.5 Hz, 2H), 1.77 – 1.47 (m, 4H), 1.46 – 1.10 (m, 4H), 0.97 – 
0.74 (m, J = 7.4 Hz, 3H). 
 
HRMS-ESI m/z [M+H]+ calcd for C23H31N2O2: 367.238005, found: 367.23829. 
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Intermediate 16 
 
 
Intermediate 16 was prepared according to general procedure by reacting scaffold A 
(63 mg, 0.28 mmol) with BocArg(Cbz)2OH (170 mg, 0.31 mmol). Intermediate 16 was 
isolated as a yellow solid (130 mg, 0.17 mmol, 60.7%). 
 
Rf=0.6 (Cyclohexane/AcOEt 5:5). 
 
1H NMR (300 MHz, CDCl3) δ=7.38-7.27 (m, 10H), 5.49 (s, 2H), 5.38 (s, 2H), 4.77 (t, J = 
6.99 Hz, 1H), 4.06-3.86 (m, 3H), 3.72-3.64 (m, 1H), 3.62 (s, 3H), 3.31-3.23 (m, 1H), 2.71-
2.74 (s, 1H), 1.91 – 1.80 (m, 2H), 1.71-1.14 (m, 13H), 1.39 (s, 10H). 
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Compound 30 
 
Compound 30 was prepared according to general procedure by subjecting 
intermediate 16 (130 mg, 0.17 mmol) to Cbz- deprotection followed by Boc- 
deprotection. Compound 30 was isolated as a off-white solid (74 mg, 0.15 mmol, 
88.2%). 
 
Rf=0.12 (Cyclohexane/AcOEt 5:5). 
 
1H NMR (300 MHz, CDCl3) δ=8.19 (s, 2H), 7.46 (m, 2H), 7.21 (m, 3H), 3.88 (m, 2H), 
3.72-3.65 (m, 1H), 3.62 (s, 3H), 3.38-3.21 (m, 3H), 2.63-2.59 (m, 1H), 2.01 (dd, J = 13.0 
Hz, 7.0, 1H), 1.94-1.74 (m, 2H), 1.66-1.08 (m, 13H), 0.95 (m, 1H). 
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Compound 31 
 
Compound 31 was prepared according to general procedure by reacting scaffold A 
(64 mg, 0.28 mmol) with 6-carboxyindole (36 mg, 0.31 mmol). Compound 31 was 
isolated as a gray solid (35 mg, 0.10 mmol, 34.6%). 
 
Rf=0.48 (Cyclohexane/AcOEt 5:5). 
 
1H NMR (300 MHz, CDCl3) δ=8.09 (d, J = 7.5, 1H), 7.01 (s, 1H), 7.64 (dd, J = 7.5, 1.5 
Hz, 1H), 7.43 (d, J = 7.5 Hz, 1H), 6.64 (d, J = 7.5 Hz, 1H), 3.95-3.86 (m, 2H), 3.62 (s, 
3H), 3.39-3.32 (m, 1H), 2.61 (m, 1H), 2.19-2.16 (m, 1H), 1.97-1.88 (m, 1H), 1.67-1-39 (m, 
7H), 1.32-1.05 (m, 4H). 
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Compound 32 
 
Compound 32 was prepared according to general procedure by reacting scaffold B 
(131 mg, 0.58 mmol) with 6-carboxyindole (103 mg, 0.64 mmol). Compound 32 was 
isolated as a gray solid (40 mg, 0.11 mmol, 19%). 
 
Rf=0.48 (Cyclohexane/AcOEt 5:5). 
 
 
1H NMR (300 MHz, CDCl3) δ=8.09 (d, J = 7.5, 1H), 7.01 (s, 1H), 7.64 (dd, J = 7.5, 1.5 
Hz, 1H), 7.43 (d, J = 7.5 Hz, 1H), 6.64 (d, J = 7.5 Hz, 1H), 3.95-3.86 (m, 2H), 3.62 (s, 
3H), 3.39-3.32 (m, 1H), 2.61 (m, 1H), 2.19-2.16 (m, 1H), 1.97-1.88 (m, 1H), 1.67-1-39 (m, 
7H), 1.32-1.05 (m, 4H). 
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